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The Role of Src Homology 2 Domain Containing Inositol-5’-Phosphatase 1 
(SHIP) in Hematopoietic Cells 
 
 
Caroline Desponts 
 
 
ABSTRACT 
The principal isoform of Src homology (SH) 2-domain containing 5’ inositol 
phosphatase protein 1 (SHIP) is a 145kDa protein primarily expressed by cells of 
the hematopoietic compartment.  The enzymatic activity of SHIP is responsible 
for hydrolyzing the 5’ phosphate of phosphatidylinositol-3,4,5-trisphosphate 
(PI(3,4,5)P3), and thereby preventing the recruitment of pleckstrin homology 
domain containing effector proteins.  Furthermore, SHIP contains protein-protein 
interaction domains, such as an SH2 domain, two NPXY and several proline-rich 
motifs.  All of these different domains endow SHIP with the capacity to impact 
signaling pathways important for proliferation, survival, differentiation and 
activation.  Therefore, we hypothesized that SHIP-deficiency could result in the 
loss of hematopoietic cell homeostasis and function 
 
To this verify this hypothesis, we first studied the effect of SHIP ablation 
on hematopoietic stem cell (HSC) proliferation, survival, function and homing.  
Most interestingly we observed that SHIP impacts HSC homeostasis and their 
  
 
xiii 
ability to home appropriately to the bone marrow.  Then, since SHIP was shown 
to be activated after engagement of the c-mpl receptor by its ligand, 
thrombopoietin, we studied the impact of SHIP deletion on the function of 
megakaryocytes, the major target cell of that cytokine.  We found that SHIP is 
also important for homeostasis of the megakaryocyte compartment.  Thirdly, we 
studied the role of SHIP in natural killer (NK) cells biology.  We observed that F4 
generation SHIP-/- mice have increased NK cells in their spleen and that these 
cells exhibit a disrupted receptor repertoire.  We verified the hypothesis that 
SHIP helps shape the receptor repertoire of NK cells, mainly through regulation 
of cell survival and proliferation.  Also included, is a study on the role of a SHIP 
isoform lacking the SH2-domain, called stem cell-SHIP (s-SHIP) in the biology of 
embryonic stem (ES) cells.  To date, this isoform is expressed by stem/progenitor 
cells and not by normal differentiated cells.  Due to its specific expression 
pattern, s-SHIP has the potential to have an important role in stem cell biology. 
 
  
 
 
 
INTRODUCTION ON SH2 DOMAIN CONTAINING 5’ INOSITOL 
PHOSPHATASE 1 (SHIP) 
 
SHIP stands for Src homology (SH) 2 domain containing 5’ inositol 
phosphatase 1 and is a protein primarily expressed by cells of the hematopoietic 
compartment.1-4  In 1996, five independent groups cloned murine SHIP using its 
ability to bind; 1) the SH3 domain of growth factor receptor-bound protein 2 
(Grb2),2 2-3) the protein-tyrosine binding domain (PTB) of SH2-containing 
sequence protein (Shc) (also called SH and collagen gene or SH2-containing 
oncogene src homology protein),3,4 4) the FcγRIIB,5 and 5) by gene trap assay.6 
 
SHIP is known to hydrolyze the 5’phosphate of phosphatidylinositol-3,4,5-
phosphate (PI(3,4,5)P3) in vivo and inositol-1,3,4,5–tetrakisphosphate (I(1,3,4,5)P4) in 
vitro,2,4 two inositides phosphates important for cell signaling (Figure 1).7-10  Since 
SHIP appears to require the presence of a phosphate on the 3’ position to exert 
its effect, it was proposed that it opposes the activity of phosphatidyl inositol 3' 
kinase (PI3K), and by doing so, regulates several cellular signaling pathways 
important for proliferation, differentiation, apoptosis and migration. 
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SHIP was first observed as a 145kDa protein that becomes tyrosine-
phosphorylated after stimulation of hematopoietic human DA-ER and MO7-ER 
cell lines with erythropoietin (Epo).11  In this particular model, stimulation of these 
cells with Epo resulted in SHIP tyrosine-phosphorylation and association with 
Shc.11  Shc being implicated in several mitogenic signaling transduction 
pathways,12 it became essential to determine the role of SHIP in hematopoietic 
cell function.  It was then determined that stimulation of several receptors 
resulted in SHIP tyrosine-phosphorylation and/or SHIP association with other 
signaling molecules such as SH2-containing tyrosine phosphatase (Shp-2),13 and 
Grb2.14,15  SHIP becomes activated after engagement of cytokines, chemokine 
and immunological receptors.  The cytokines that have been identify to stimulate 
SHIP consist of interleukin (IL)-3,13,16-18 IL-4,19,20 macrophage colony stimulating 
factor (M-CSF or c-FMS),21 granulocyte-macrophage-CSF (GM-CSF),16,18 
granulocyte-CSF(G-CSF),22,23 Stem Cell Factor (c-KitL or SCF),1,16 
thrombopoietin (TPO),24,25 Fms-like tyrosine kinase 3 ligand (Flt3L).26  The major 
chemokine known to induce SHIP recruitment is stromal cell derived factor-
1/CXCL12 (SDF-1) which binds to the CXCR4 receptors on multiple 
hematopoietic cells.27,28  The immunological receptors known to recruit SHIP are 
the Fc receptor,5,29,30 the T cell receptor,31 and B-cell-receptor Ig-α and Ig-β 
chains.32-34  Once SHIP is activated or recruited by these receptors, it can 
dampen the levels of PI(3,4,5)P3, phosphorylation of Protein Kinase B (Akt or 
PKB), accumulation of intracellular calcium, the formation of the protein complex, 
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composed of Shc, Grb2, and Son of Sevenless (SOS), and by doing so, SHIP 
negatively regulates the activation of the mitogen-activated protein kinase (MAPK 
or Erk) pathway (Figure 1).  For example, SHIP impacts pathways downstream of 
G-CSF receptors that tightly regulate proliferation and survival of neutrophils.22,23  
The cytoplasmic tail of the G-CSF receptor contains a region that is responsible 
for recruiting PI3K and stimulating proliferation and survival signaling pathways.22  
On the other hand, this same receptor has another region on its cytoplasmic tail 
that can recruit the SHIP/Shc complex, this region is associated with negative 
regulation of proliferative signaling.22  This demonstrates the great balancing act 
in which these molecules are involved. 
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Figure 1.  Signaling pathways influenced by SHIP.  Engagement of receptor by its ligand 
leads to recruitment of SHIP with can impact different signaling pathway.  1) SHIP can 
prevent the Grb2/SOS from binding to Shc, thus preventing the activation of RAS and 
the downstream MAPK pathway. 2)  Alternatively, SHIP can hydrolyze the 5’ phosphate 
of PI(3,4,5)P3 generating PI(4,5)P2.  This prevents the recruitment of pleckstrin homology 
(PH) containing protein to the membrane and their activation.  In this manner, SHIP 
prevents activation of Bruton’s tyrosine kinase (Btk), which is responsible for 
phospholipase Cγ (PLCγ) activation, leading calcium entry and MAPK activation.  SHIP 
also dampens the recruitment and activation of Akt, which leads to phosphorylation of 
proteins in the Bcl family, such as BAD, Bcl-2, BclXL, preventing apoptosis.  
Furthermore Akt can phosphorylate Forkhead (FH) and prevent its translocation to the 
nucleus.35,36  Consequently, FH is prevented from inducing transcription of cell death 
related genes such as Fas ligand (FasL).35 
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SHIP Structure and Cell Signaling 
 
The SHIP protein sequence contains several interaction domains including 
an SH2 domain, a 5’inositol phosphatase, several proline-rich domain, and two 
NPXY motifs (Figure 2A).  Full length SHIP is a 145kDa protein,11 which has 
several isoforms that have different molecular weight including an 130kDa or 
135kDa isoform in human and murine cells, respectively, and an 110kDa isoform 
found in both human and murine cells (Figure 2).4,37  All of these isoforms appear 
to have lost a specific protein domain when compared to full length SHIP, which 
could lead to having a different function in the cell. 
 
SH2 Domain 
 
The SH2 domain of SHIP, stands for Src homology domain 2, a structure 
that has the potential to bind to phosphotyrosine.   Using this domain SHIP 
can bind to phosphorylated immuno-receptor tyrosine based activation or 
inhibition motifs (ITAMs or ITIMs)  present in the cytoplasmic tail of several 
receptors, such as FcγRIIB (ITIM) on B cells,  Ly49A and C receptors on 
natural killer (NK) cells,  and FcRεI (ITAM) on mast cells.   
38,39
5,40
5,41
42,43 40,44 The SH2 
domain of SHIP was also shown to interact with the Src kinase Lyn,45 which can 
phosphorylate SHIP.46  This stabilizes SHIP near the membrane and enhances 
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its capacity to regulate the Akt signaling pathway.45  It is important to note that 
location more than phosphorylation contributes to SHIP phosphatase activity.46  
Furthermore, it was shown that the SH2 domain of SHIP interacts with tyrosine-
phosphorylated Shp-2.   Since a SHIP mutant, with a deleted SH2 domain, 
can not be phosphorylated or bind to Shc nor Shp-2 after stimulation with IL-3, it 
was suggested that this domain is crucial for SHIP function.   Consistent 
with this observation, we found that a SHIP isoform lacking the SH2 domain 
called stem cell-SHIP (s-SHIP) (Figure 2) can not get phosphorylated and is 
unable to associate with Shc after stimulation of embryonic stem (ES) cells with 
leukemia inhibitory factor (LIF).   The SH2 domain of full-length SHIP appears to 
compete with Grb2 for interaction with the same phosphorylated tyrosine on 
Shc.   Interaction of Shc with Grb2 would lead to the recruitment of a protein 
complex including SOS, which catalyzes the exchange of GDP to GTP on RAS, 
resulting in the activation of the MAPK/Erk pathway.   Thus, SHIP prevents 
formation of this complex and negatively regulates MAPK activation (Figure 1).  
Although this hypothesis is compelling, it is important to keep in mind that Shc 
could associate with SHIP through a different mechanism.  For example, it has 
been proposed that Shc PTB domain can bind the phosphorylated tyrosine Y917 
and Y1020 on the NPXY motifs of SHIP.   Studies using a SH2 domain deleted 
SHIP mutant revealed that this domain is necessary for the NPXY motifs to 
become phosphorylated  and for SHIP to interact with Shc.   Therefore, it 
becomes difficult to exactly determine which domain between the SH2 and NPXY 
domain is used by SHIP to bind to Shc.  Another protein with which SHIP 
13,17
13,47,48
49
1
1
50
48 50
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interacts through its SH2 domain is Gab1.   However, in this case it is 
impossible to rule out if SHIP and Gab1 associate directly or through 
intermediary molecules, since they are found in a multi-protein complex involving 
phosphorylated Shp-2, PI3K, and Shc.  
51
51,52
 
Figure 2.  Schematic representing different SHIP isoforms structure.  (A) Full-length 
SHIP, is SHIP and 145kDa.  (B)SHIPβ is app. 130kDa and lacks 183 amino acids 
between the NPXY 
motifs, resulting in the 
deletion of a proline-
rich domain and the 
amino acids adjacent 
to the first NPXY 
motif, IGM, which 
would be important for 
p85 subunit binding.  
(C) SHIPδ is the result 
of the deletion of all 
the proline-rich regions and the last NPXY motifs.  The last 62 amino acids at the c-
terminal are changed from the full length SHIP, caused by an out-of-frame 230 amino 
acids deletion.  Depending on the reports the SHIPβ and SHIPδ are either the result of 
proteolytic cleavage37 or alternative splicing.53,54  (D) Stem cell-SHIP (s-SHIP) is 
expressed from the same chromosomal region but has an alternative promoter/start site 
than the SHIPα, situated in the intron5/6 of SHIPα.  This was first proposed in a paper 
we published in 200149 and then confirmed by Rohrschneider et al.55  A 125kDa isoform 
that is probably generated through truncation of the 145 full-length SHIP c-terminal 
exists, however this isoform has not been sequenced, thus the structure is not available. 
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5’ Inositol Phosphatase 
 
PI3K catalyzes the addition of a phosphate at the 3’ position on 
Phosphatidyl Inositol(4,5) Phosphate (PI )P2), creating PI P3, this molecule 
allows the recruitment of pleckstrin homology (PH) domain containing proteins 
(e.g.: Akt, phosphoinositide dependent kinase 1 (PDK1), Bruton’s tyrosine kinase 
(Btk)), which can then stimulate proliferation, survival, and activation 
pathways.   SHIP, by removing the 5’ phosphate of PI P3, can prevent 
the recruitment of these effector molecules and negatively regulate some of PI3K 
downstream signaling pathways.   In particular, SHIP has been shown to 
decrease Akt recruitment and phosphorylation, leading to a decrease in survival 
and proliferation signaling.   Furthermore, the degradation of PI P3 by 
SHIP after it is recruited to co-ligated B cell receptor (BCR) and FcγRIIB1 can 
lead to a reduction in Btk membrane localization, which would prevent its 
activation, resulting in a subsequent decrease in PLCγ2 activity and stopping of 
calcium flux.   On the other hand, the ability of SHIP to remove the 5’ 
phosphate of I P4 could limit the extracellular entry of calcium and 
negatively control cell activation.   There is no requirement for SHIP to be 
phosphorylated  before it can hydrolyze the 5’ phosphate of PI P3 or 
I P4, suggesting that localization of SHIP in proximity to the target molecule 
is the determining mechanism of activation.  
(4,5 (3,4,5)
10,56-59
(3,4,5)
10,56-59
60,61
(3,4,5)
62,63
(1,3,4,5)
64-66
(4,3,5)
(1,3,4,5)
54
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NPXY Motifs 
 
NPXY stands for arginine (N), proline (P), any amino acid (X), and tyrosine 
(Y), and there are two on the carboxyl-terminus of SHIP (Figure 2).  This motif 
can become tyrosine phosphorylated upon activation, which becomes a potential 
binding site for some PTB domain containing protein.67-69  In this manner, it was 
proposed that the PTB domain of Shc could interact with the phosphorylated 
tyrosines of the NPXY motifs on SHIP, in particular Y917 and Y1020.2,50  
Furthermore, a SHIP isoform, SHIPδ, in which the 2nd NPXY motif and all the 
poly-proline rich stretch has been deleted can not bind to Shc.52  However, as 
mentioned earlier, depending on the cell context, it appears that SHIP can also 
interact with Shc, through its SH2 domain binding to the phosphorylated Y187 on 
Shc, a site for which SHIP and Grb2 are competing in order to exert opposite 
effects on the Ras/MAPK pathway.1  Although the nature of these conflicting 
results will not be further discussed in this dissertation, they are worth mentioning 
to emphasize that more work needs to be done to fully understand the function of 
SHIP in the different cell context. 
 
Another protein that has been found to interact with the NPXY motifs of 
SHIP is the p85 subunit of PI3K.14,70,71  Of the two NPXY motifs present on the 
carboxyl terminal region of SHIP, the first one is followed by a consensus 
sequence for the binding of the p85 subunit of PI3K, isoleucine-glycine-
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methionine (IGM).53,71,72  It was shown that p85 PI3K subunit interacts with SHIP 
only when the first NPXY region is tyrosine-phosphorylated.53,71 
 
Proline Rich (PxxP) Region 
 
PxxP motifs are spread between the 1st and 2nd and after the 2nd NPXY 
motifs within the carboxyl terminus of SHIP (Figure 2).  PxxP motifs are known to 
interact with SH3 motifs,73 To this effect,  SHIP can associate with Grb2, a 
protein containing two SH3 domains flanking an SH2 domain on each side.  
Immunoprecipitation assays have shown that Grb2 can associate with SHIP and 
s-SHIP.2,4,49 
 
SHIP Isoforms 
 
As mentioned above, several SHIP isoforms have been identified, mostly 
through immunoblots.  In humans it was shown that peripheral blood (PB) cells 
expressed a 100kDa version of SHIP, while CD34+ acute myeloblastic leukemia 
cells expressed 130kDa and 145kDa.74  In the murine system, most of the lower 
molecular weight isoforms, the 110, 124, and 135kDa isoforms bear a deletion in 
the c-terminus region, and appear to be generated from the full-length 145kDa 
SHIP,3,5,53 either by proteolytic cleavage37,75,76 or alternative splicing.52  
Importantly, the 110kDa SHIPδ isoform (Figure 2C), which lacks the proline-rich 
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region and the 2nd NPXY motifs at the carboxyl terminus, exhibit reduced 
phosphorylation and interaction with Shc after stimulation of FD-FMS cells by M-
CSF.52  Lucas and Rohrschneider (1999) reported the co-expression of a 135kDa 
and 145kDa SHIP isoforms in a series of macrophage, B cell progenitor, and T-
cell cell lines.53  This 135kDa isoform results from the internal deletion of a PxxP 
containing stretch between the 2 NPXY motifs due to alternative splicing.  This 
isoform, which was called SHIPΔ183, can still bind to Shc and Grb2 but has 
reduced affinity for the p85 subunit of PI3K.53  This is explained by the deletion of 
an important consensus sequence after the first NPXY motif, leading to a change 
in the following amino acids from YIGM to YIAN.  The elimination of the 
methionine at the +3 position after the tyrosine reduces the ability of p85 PI3K 
subunit to bind SHIPΔ183.53 
 
Even though most of the isoforms isolated seem to involve cleavage or 
alternative splicing in the carboxyl-terminal of SHIP, another 110kDa isoform 
lacking the SH2 domain was identified in human4 and in mice.49  The human 
110kDa isoform, called SIP-110, isolated by Kavanaugh et al lacks 214 amino 
acids at the amino-terminus, resulting in the absence of the SH2 domain.4  It was 
proposed at the time that SIP-110 isoform resulted from alternative splicing of the 
full length SIP-145 mRNA.4  In 2001, our laboratory published that murine ES 
cells express a 110kDa SHIP isoform (calculated MW 104kDa), called s-SHIP.  
This isoform lacks 263 amino acids at the amino-terminus.49  In that study, we 
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proposed that s-SHIP and SIP-110 were homologues, and were both the result of 
an alternative start site.  The promoter region of that isoform being present in the 
in the intron 5/6.49  This was confirmed in a study by Rohrschneider et al, which 
showed that intron 5/6 had promoter activity able to drive the expression of a 
reporter gene in stem/early progenitor cells in vivo.55  Importantly, s-SHIP is 
expressed in ES cell and hematopoietic stem cells (HSC) but not in normal 
lineage differentiated cells.49,55  This characteristic makes it a very important 
isoform that certainly should be investigated further for its possible role in stem 
cell biology. 
 
Inositol Phosphatases with a Redundant Function to SHIP 
 
SHIP2 
 
A 150-155kDa protein with 38% amino acid sequence homology to SHIP1 
was identified by Pasesse et al (1997), and was named SHIP2.   It was later 
found that this protein had already been isolated as 51C protein also called 
inositol polyphosphate-like-protein1 (INPPL-1), which is an inositol phosphatase 
with the potential to complement the Fanconi anemia group A gene defect.   
While murine SHIP1 is expressed from chromosome 1 and its human homologue 
from chromosome 2, SHIP2 is expressed from Chromosome 7 in mouse and 8 in 
human.   However, although SHIP2 reside on a different chromosome, it 
77
78
79
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contains most of the hallmark domains of SHIP1.  For example, SHIP2 has an 
amino-terminal SH2-domain with 54% identity and a 5’inositol phosphatase with 
64% homology to the one found in SHIP1.   SHIP2 also has several poly-proline 
rich stretches in its carboxyl terminal (up to 8), where SH3-domain containing 
protein can bind and one NPXY motif, a site where PTB domain can bind.  This 
could account for SHIP2 ability to interact with Shc.   Whereas SHIP1 
expression appears to be restricted to hematopoietic cells, it was reported that 
SHIP2 is ubiquitously expressed, being observed in hematopoietic cells, such as 
T cells, B cells, thymus and spleen  and in non-hematopoietic tissues such as 
brain and skeletal muscle.   Like SHIP1, SHIP2 has the potential to influence 
many signaling pathways.  For example, like SHIP1, SHIP2 has been shown to 
associate with the ITIM domain of FcγRIIB in B cells under negative signaling.   
Furthermore, IL-3, c-KitL, and GM-CSF stimulated the phosphorylation and 
interaction of SHIP2 with Shc in hematopoietic cells. .  Another example of the 
importance of SHIP2, is its ability to be recruited to epidermal growth factor 
(EGF) receptor where it hydrolyzes the 5’ phosphate of PI P3 after EGF 
stimulation of COS-7 cells.  More importantly, SHIP2 has been shown to control 
insulin receptor signaling in vitro  and in vivo, in a knock-out model.   
Different groups have shown that SHIP2 over-expression led to a decrease in 
insulin signaling whereas a SHIP2 deficiency led to an increase in insulin 
sensitivity.   It is important to mention that since SHIP2 interacts with different 
molecules than SHIP1 and that it can not hydrolyze the 5’ phosphate of 
77
80
81
77,82
83
80
(3,4,5)
84-87 88
84-89
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I P4, even though these molecules have great homology they are not simply 
redundant molecules, but have defined purpose in the cells. 
(1,3,4,5)
 
Phosphatase and Tensin Homolog Deleted on Chromosome Ten 
 
The defect observed in SHIP-/- mice is severe, but at the same time is 
probably compensated for by different phosphates such as SHIP2, s-SHIP or 
phosphatase and tensin homolog deleted on chromosome ten (PTEN).  PTEN is 
a 54kDa ubiquitously expressed tumor suppressor inositol phosphatase that can 
hydrolyze the 3’ phosphate of PI(3,4,5)P3, thus, counteract PI3K activity and 
contribute to the control of Akt activation.90  PTEN also has a modest capacity to 
dephosphorylate tyrosine phosphorylated proteins.91  PTEN is one of the most 
commonly inactivated genes in several type of cancers92 and a key regulator of 
cell growth and apoptosis.93  The major function of PTEN appears to be the 
reduction of basal PI(3,4,5)P3 levels and Akt activity in a constitutive manner,90 and 
not upon stimulation by growth factor like SHIP.  Therefore, its ablation leads to a 
more severe phenotype than in SHIP-/- mice, in fact PTEN-/- are embryonic 
lethal,94 further suggesting that PTEN is important for normal development.  
Interestingly, PTEN+/- and SHIP-/- mice share many characteristics, suggesting 
that the phenotype observed in both mice result mainly from the accumulation of 
PI(3,4,5)P3.95,96 
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Study of SHIP Function Using SHIP Knock-Out Models 
 
The study of SHIP knock-out (KO) mouse models has given great insight 
into SHIP function in the hematopoietic system.43,95,97  Although SHIP expression 
is detectable during embryogenesis at day 7.5 post-coitus,98 SHIP KO mice are 
viable.43,95,97  However, they suffer from a myeloproliferative disorder, that causes 
an increase in macrophage progenitor and mature macrophage numbers in the 
BM, spleen and periphery.95  These macrophages infiltrate the lung of SHIP-/- 
mice, and this is the suspected cause for their demise at 8 to 12 weeks of age.95  
Using SHIP KO mouse model, it was shown that SHIP negatively regulates the 
phosphorylation and activation of Akt through downregulation of PI(3,4,5)P3 in B 
cells,61 in myeloid cells,18 and NK cells.43  Huber et al also showed that through 
binding to FcεRI in mast cells,40,44 SHIP can downregulate their degranulation 
after stimulation of c-Kit receptor with its ligand.99  The stimulation of mast cells 
leads to the activation of PI3K and the production of PI(3,4,5)P3, which can then 
stimulate the entry of extracellular calcium,99,100 and the release of granule 
content.  Interestingly, SHIP KO mice were also shown to suffer from 
osteoporosis caused by hyper-resorptive osteoclasts.101  This could disrupt the 
BM matrix and perturb the HSC niche. 
 
Most of our studies were done using the SHIP-deficient mouse model 
generated in our laboratory.  These mice were created by targeting the promoter 
 
15 
  
and exon 1 of the SHIP gene using the Cre-loxP strategy and we refer to it as 
SHIP-/- (Figure 3).43  In this model, the region to be deleted is flanked (floxed) by 
two recombinase (Cre) recognition sites, called loxP, which were introduced by 
homologous recombination in ES cells.102  In order to get deletion of the targeted 
region, the 34 base pair loxP sites need to be inserted in the same orientation.103  
Once a germline flox/flox or flox/+ animal is obtained, it is crossed with a Cre+/+ 
mouse, which result in the deletion of the targeted region.  The resulting mice 
can then be used to generate germline knockout mice.  This system allows 
deleting or targeting the gene of interest either in the entire animal or specific cell 
type dependent on the promoter that is used for Cre expression.  The other SHIP 
KO model used in our laboratory was a kind gift from Dr. Ravetch at the 
Rockefeller University in New York.  His team produced that model by targeting 
the region that encodes part of the inositol phosphatase region using the CRE-
loxP strategy (Figure 3).97  Consequently, this mouse model will be referred to as 
SHIPΔIP/ΔIP.  The SHIPΔIP/ΔIP mice were mainly used less frequently and mainly to 
confirm the results obtained with SHIP-/- mice to ensure that different mutations of 
the same gene lead to the same phenotype. 
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Figure 3.  Two SHIP KO models, SHIP-/- and SHIPΔIP/ΔIP.  (A) Our laboratory created the 
SHIP-/- model using 129SvJ ES cells, Cre-loxP recombinant technology. The promoter 
region and the exon 1 of SHIP were targeted.43  The SHIPΔIP/ΔIP model was created using 
the same technology 
but targeting the exon 
10 and 11, which 
form part of the 
inositol phosphatase 
region.97  (B) Both of 
these knockout mice 
do not express SHIP.  
(i) Western blot done on littermates of a mating between heterozygote male and female, 
harboring a deletion of the promoter and first exon, SHIP-/-.43  (ii) Western blot done on 
littermates of a mating between a heterozygote male and female, harboring a deletion of 
exon 10 and 11, SHIPΔIP/ΔIP.97  The later mouse model was generated in the laboratory of 
Dr. Ravetch at Rockefeller University, New York, USA.97 
 
17 
  
 
 
 
RESULTS 
Section I SHIP-Deficiency Enhances HSC Proliferation and Survival but 
Compromises Homing and Repopulation 
 
Introduction 
HSC Development 
 
 
HSC are responsible for the maintenance of the hematopoietic 
compartment throughout an organism’s lifespan (Figure 4).  These cells have the 
ability to self-renew, differentiate into all hematopoietic lineage and to 
reconstitute a lethally irradiated host.  In the mouse, the embryonic or primitive 
HSC appear in the yolk sac at day E7 of embryonic development.104,105  These 
cells participate in transient hematopoiesis during embryogenesis giving rise 
mainly to nucleated erythrocytes,106 although some studies have shown that 
putative yolk sac HSC have long-term multilineage repopulation capacity,107 
suggesting that they have he potential to differentiate into several hematopoietic 
lineage.  At day E10, the definitive HSC is found in the aorta-gonad-
mesonephros (AGM).108,109  Only these HSC will have the ability to establish 
definitive hematopoiesis and to reconstitute a lethally irradiated adult host.104,108-
110  Later during fetal development the definitive HSC migrate to the fetal liver, to 
the spleen and shortly thereafter birth all hematopoiesis is concentrated mainly in 
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the BM.104  The maintenance of the hematopoietic compartment depends on 
HSC homeostasis, the balance between self-renewal, proliferation, apoptosis, 
and migration (i.e. homing and mobilization) of HSC.  Several factors responsible 
for HSC homeostasis have been identified, nevertheless more information is 
needed. 
 
Figure 4.  Hematopoietic compartment.  HSC have the potential to self-renew without 
limits, differentiate and produce all the cells necessary for a functional hematopoietic 
compartment.  This differentiation occurs through a series of intermediaries (often called 
progenitors), which usually have the potential to self-renew with limitations and to 
differentiate into a defined cell type. 
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Cytokines Impacting HSC Self-Renewal 
 
It is well accepted that the niche in which the HSC reside in the BM is 
responsible for the retention of HSC and their ability to self-renew, differentiate, 
or apoptose.  Cell-to-cell contact and external signaling plays a major role in that 
process.  Several cytokines have been shown to influence HSC proliferation and 
self-renewal in vitro and in vivo.  In fact, several in vitro studies have shown that 
TPO alone or in combination with c-KitL, IL-3, or Flt3L111-115 can stimulate the 
proliferation of early human and murine hematopoietic progenitors.116-127  Most 
importantly, expansion of early progenitor cells in the presence of TPO with c-
KitL or Flt3L confer these cells with the ability to self-renew, to retain a primitive 
phenotype and maintain the capacity for multilineage differentiation for a defined 
number of cell division.116,119-121,123-125  It was also shown that tumor necrosis 
factor-α (TNF-α) can stimulate the self-renewal and proliferation of human 
CD34++CD38- in vitro in the presence of IL-3, potentially in a synergistic 
manner.128  Most importantly, maintenance of hematopoiesis in vivo depends on 
the presence of osteoblast and stromal cells that will form the niche.  This 
microenvironment will promote HSC homeostasis.  Furthermore, several factors 
that are important for maintenance of HSC have also been shown to impact 
homing and retention of HSC to the BM niche. 
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BM Homing and Retention of HSC 
 
 
The homing process was characterized as a 3 step process; 1) Loose or 
rolling interaction of cells with vascular endothelium, 2) Firm adhesion to the 
vessel or sinus, 3) Diapedesis through the endothelial layer.129  This process first 
requires the presence of specific cytokines and of cell adhesion molecule (CAM) 
that will mediate the associate of HSC with the stromal cells and osteoblasts that 
compose the niche in the endosteal region in the BM that support HSC 
homeostasis.130-135  To this effect, HSC can interact with a series of molecules 
produced by the BM stroma such as extracellular matrix (ECM) components, 
CAM mediating cell-cell adhesions, and endothelial selectins.  The ECM 
components are fibronectin,136,137 hyaluronic acid,138 laminins,139 collagen, and 
thrombospondin.140 The CAM mediating cell-cell adhesions include the 
intracellular cell adhesion molecule-1 (ICAM-1/CD54) and vascular cell 
endothelial molecule-1 (VCAM-1 or CD107).141,142  The endothelial selectins are 
P-selectin/CD62P and E-selectin/CD62E.143,144  All of these molecules are 
ligands for receptors present on HSC.  These receptors, once engaged will lead 
to HSC attachment and establishment in the BM niche and thus, contribute to 
HSC homeostasis.  For example, very-late-antigen 4 (α4β1, CD49d/CD29 (VLA-
4)) is expressed by hematopoietic cells including HSC and can bind fibronectin 
and VCAM-1 present on endothelial cells.  VLA-4 can promote initial capture, 
rolling and firm cell adhesion to the endothelial cells.145  In previous studies, in 
vitro stimulation of murine BM stem/progenitor cells with different cytokines was 
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shown to induce cell cycle, decrease VLA-4 expression and resulting in 
compromised engraftment.146,147  Most importantly it was shown that engagement 
of VLA-4 an VLA-5 receptors can lead to HSC quiescence,148 an important 
aspect of HSC biology.  Most importantly, HSC quiescence protects the 
compartment against external insult and insure the organism that the 
hematopoietic compartment will be replenish once the insult is cleared. 
 
Proper homing of the HSC to the BM also depends on the presence of a 
chemokine, SDF-1 also called CXCL-12 and the engagement of its receptor on 
HSC, CXCR4.  The CXCR4 receptor induces cell migration towards an 
increasing gradient of SDF-1.149  Treatment of NOD/SCID mice with SDF-1 leads 
to the mobilization of HSC to PB150 and treatment of human HSC with anti-
CXCR4 antibody prior to transplantation in NOD/SCID mice results in HSC 
engraftment failure.151  Furthermore, CXCR4 and SDF-1-deficient mice are 
embryonic lethal since HSC fail to migrate from the fetal liver to the BM, where 
definitive hematopoiesis would take place.  Interestingly, SHIP-/- myeloid 
progenitor cells have been shown to migrate more efficiently towards SDF-1 
compared to WT myeloid progenitors.152  Furthermore, SHIP appears to be 
recruited to the membrane upon CXCR4 engagement by SDF-1.27 
 
SHIP in HSC Biology 
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As mentioned earlier, the survival of an organism is dependent upon the 
ability of HSC to replenish the blood compartment on a daily basis (Figure 4).  To 
accomplish this task, HSC must maintain a fine balance between three possible 
fates: self-renewal, differentiation or senescence.  Although the decision process 
that determines the fate of an HSC clone remains to be completely defined, 
several molecules are already known to play a role in this process, including 
components of the HSC microenvironment or niche.  This niche consists of both 
extra-cellular matrix molecules and cells, such as osteoblasts and stromal cells 
that produce cytokines and chemokines important for the maintenance of the 
HSC pool.131-135 
 
 
These microenvironmental or external cues engage receptors on HSC, 
leading to the activation of signaling pathways governing cell proliferation, self-
renewal, differentiation, mobilization and BM retention.135  Some of these 
pathways, such as those initiated by c-KitL,153 SDF-1,154 IL-3,155 Flt-3L,111-115 and 
TPO,17 result in the activation of PI3K and the formation of PI(3,4,5)P3.  Therefore, 
SHIP may influence these pathways in HSC.47,152  SHIP is a 145kDa protein 
primarily expressed by cells of the hematopoietic system,3 including HSC,49 that 
can associate with various adapter proteins, scaffold proteins, or receptors 
following activation of hematopoietic cells.18,152  Formation of these complexes 
enables SHIP to hydrolyze the 5’phosphate on PI(3,4,5)P3,2,3 thus preventing 
membrane recruitment and activation of pleckstrin homology domain containing 
kinases that serve as effectors of PI3K signaling.  This activity permits SHIP to 
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limit the survival, activation, differentiation and/or proliferation of hematopoietic 
cells.47  Thus, we hypothesized that SHIP might also influence these processes 
in the HSC compartment.  Previous studies reported that SHIP-/- whole bone 
marrow (WBM) cells do not reconstitute lethally irradiated mice as well as wild-
type (WT) WBM in a non competitive setting.156  Furthermore it was reported that 
SHIP-/- WBM has comparable numbers of competitive-repopulating-units (CRU) 
relative to WT littermates in a limiting-dilution assay, which uses compromised 
competitor cells.156  However, because these analyses were performed with 
WBM rather than purified HSC, they did not assess whether SHIP-/- HSC are 
defective for repopulation in a WT environment.  Thus, it is not possible from 
these previous studies to conclude that SHIP plays a direct role in signaling 
pathways essential for HSC function. 
 
 
To study the role of SHIP in HSC we used SHIP-/- mice generated by a 
Cre-lox mutation strategy.43  We found that SHIP-/- mice contain significantly 
more HSC in their BM, spleen, and blood as measured by flow cytometry.  We 
also observed that a greater proportion of SHIP-/- HSC enter the cell cycle 
compared to WT HSC.  Since it was shown in previous studies that SHIP-/- BM 
contains reduced HSC activity relative to WT BM,156 it became important to 
assess the function of SHIP-/- HSC in different assays.  We found that when 
purified SHIP-/- HSC or WBM are transplanted into lethally irradiated mice, they 
failed to compete effectively with WT HSC or BM cells for long-term multi-lineage 
repopulation of the hematopoietic compartment.  These results might have 
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suggested that the absence of SHIP causes accelerated senescence of the HSC 
compartment.  However, we observed fewer apoptotic HSC in SHIP-/- BM as 
compared to WT BM.  We then assessed the ability of SHIP-/- HSC to reach the 
BM niche, where they encounter the proper environment to support their function.  
In vivo homing studies performed using purified stem/progenitor cells suggest 
that SHIP-/- cells home to the BM with a decreased efficiency compared to WT 
cells.  Most interestingly, we also observed that SHIP-/- HSC have significantly 
lower surface expression of CXCR4 and VCAM-1, key receptors for homing and 
retention of hematopoietic cells in the BM.151,157,158  Therefore, SHIP plays an 
important role in regulating HSC proliferation, survival, self-renewal, as well as 
BM homing and retention. 
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Aims: 
1) Quantitate the HSC compartment in different hematopoietic organs of SHIP-
deficient mice as compared to WT by flow cytometry. 
2) Assess if SHIP-/- HSC are functional in a transplant assay.  This is the only in 
vivo assay to measure HSC ability to self-renew and differentiate into cells of 
the hematopoietic compartment. 
3) Determine why SHIP-/- HSC do not engraft as efficiently as WT HSC; Are they 
short-term HSC?, do they lack the ability to differentiate in a transplant 
setting?, are they more prone to apoptosis due to the osteoporotic phenotype 
observed in SHIP-/- BM?, are they deficient in their ability to engraft? 
 
Results 
 
SHIP-/- Mice Have an Expanded HSC Compartment 
 
We initially quantitated HSC numbers based on a phenotype established 
by Morrison et al., Lin-/lowThy1+c-Kit+Sca1+ (KTLS),159 which are highly enriched 
for long-term repopulating HSC (LT-HSC) activity.159  We found that SHIP-/- mice 
have an increased percentage and absolute number of KTLS cells in their BM, 
spleen (Table 1) and PB (data not shown). 
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Table 1.  Increased numbers of HSC cells in the BM and spleen of SHIP-/- mice 
compared to WT littermates. n at least 3 for each genotype, ♦ spleen 
  % over WBM cells  Abs. #/pair of femur + tibia or Abs#/spleen (x103)  
Population  SHIPΔIP/ΔIP  WT p SHIPΔIP/ΔIP  WT p 
Lin-Sca1+ 
c-Kit+Thy1low
BM 0.276±0.024 0.041±0.008 0.0005 46.24±8.01 16.95±4.18 0.0343 
 spl
♦ 0.1767±0.0481 0.01±0.001 0.0255 89.2±28.2 2.93±0.282 0.0375 
Population  SHIP
-/- WT p SHIP-/- WT p 
Lin-Sca1+ 
c-Kit+Thy1low
BM 0.4114±0.0353 0.0725±0.025 <0.001 205.3±33.9 37.9±15.3 0.001 
 spl 0.0957±0.0131 0.0142±0.0040 0.004 50.90±9.25
 5.80±1.92 0.01 
Lin-Sca1+c-Kit+ 
Flk2-
BM 0.2860±0.0398 0.1340±0.0202 0.01 221.4±45.9 103.0±72.2 0.03 
 spl 0.0827±0.0141 0.027±0.002 0.02 52.10±7.89
 13.58±0.75 0.008 
Lin-Sca1+c-Kit+ 
CD48-
BM 0.019±0.002 0.0068±0.0006 0.001 7.84±0.95 2.76±0.30 0.001 
 spl 0.0020±0.0003 0.0002±0.0001 0.005 5.53±0.073
 0.289±0.087 0.002 
Lin-Sca1+c-Kit+
CD48-CD150+
BM 0.0008±0.0001 0.0004±0.0001 0.04 0.35±0.019 0.164±0.062 0.045 
Side population 
(SP) 
BM 0.0565±0.0044 0.0290±0.0044 0.004 26.7±4.7 12.5±2.4 0.035 
 
BM of SHIPP-/- mice contained 6-fold more KTLS cells than WT controls 
(Table 1).  In the spleen of SHIP-/- mice, we observed a greater than 6-fold 
increase in the percentage and absolute numbers of KTLS cells (Table 1).  A 
comparable scenario was seen in the PB, where KTLS cell percentage was 
increased by 2.5–fold as compared to WT littermates (data not shown).  A similar 
expansion of the KTLS compartment was observed in SHIPΔIP/ΔIP mice, another 
germline SHIP mutant model with a different genetic background.97  As for the 
SHIP-/-, SHIPΔIP/ΔIP BM and spleen exhibited a significant increase in KTLS cells 
when compared to WT control (Table 1).  The percentage of KTLS present in 
SHIPΔIP/ΔIP BM and spleen were 6.7 and 2.7-fold higher than observed in WT 
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control.  Furthermore, KTLS absolute numbers were increased 18.2-fold in the 
BM and 30.4-fold in spleen of SHIPΔIP/ΔIP mice as compared to WT controls. 
 
Although Thy1.2 expression can be detected on HSC from C57BL6/J 
mice, surface expression is lower, making negative and positive distinction more 
difficult than for the Thy1.1 allele.160,161  Thus, we also quantified HSC numbers 
using different phenotypes, including the immunophenotype defined by 
Christensen et al:160 Lin-/lowFlk2-c-Kit+Sca1+ (KFLS).  KFLS cells, as opposed to 
KTLS, can be used regardless of genetic background.160  We found that SHIP-/- 
mice also exhibited an increased percentage and absolute number of KFLS cells 
in their BM and spleen (Table 1).  KFLS cell numbers are expanded by 2-fold in 
the BM of SHIP-/- mice relative to WT mice.  We also observed that both the 
percentage and absolute numbers of KFLS cells in SHIP-/- spleens were 
increased by more than 3-fold as compared to WT spleens (Table 1).  In addition, 
Kiel et al recently published a new phenotype to identify HSC that relies on the 
differential expression of the SLAM family receptors, CD48 and CD150, by HSC 
and MPP.162  We observe a 2.8-fold increase in the number of KLSCD48- cells in 
SHIP-/- BM compared to WT BM (Table 1, Figure 5A, B). Moreover, the 
percentage and absolute numbers of KLSCD48- cells are increased by 8.7 and 
19-fold, respectively in SHIP-/- relative to WT spleen (Table 1, Figure. 5A, B).  
When using the KLSCD48-CD150+ immunophenotype we detect a 2-fold 
increase in the number of HSC in the BM of SHIP-/- BM as compared to WT 
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(Table1).  In order to confirm our observations made using immunophenotypes 
relying on surface marker expression, we assessed the level of HSC using the 
side population (SP) phenotype.  Identification of SP cells relies on the function 
of a transporter protein that exclude the dye Hoechst 33342,163,164-- these cells 
are enriched ~1000-fold for LT-HSC activity compared to WBM cells.163  When 
comparing SHIP-/- vs. WT BM, we observed a 2-fold increase in the percentage 
and absolute number of SP cells in SHIP-/- BM (Table 1).  Thus, analysis of five 
different HSC phenotypes159,160,162,163 demonstrated a preferential expansion of 
the LT-HSC compartment in SHIP-/- mice.  These observations implicate SHIP in 
the control of HSC compartment homeostasis. 
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Figure 5.  Significant increase in the percentage and absolute number of KLSCD48- cells 
in SHIP-/- BM.  (A) Representative 
FACS plots showing detection of 
KLSCD48- HSC in SHIP-/- and WT 
BM.  (B) Percentage and absolute 
number of KLSCD48- cells in the 
BM (per femur and tibia pair) and 
spleen (Spl) of SHIP-/- (square) and 
WT (triangle) mice. Data acquired 
on a FACS Aria with DiVa (BD 
Biosciences, San Jose, CA) 
software, analyzed with FlowJo 
(Tree Star Inc., Ashland, Oregon).  
(C) Histogram of DNA content in 
SHIP-/- and WT KTLS cells. (D) Bar 
graph showing the percentage of 
SHIP-/- (black) or WT (grey) 
KTLS/KFLS cells in each stage of 
cell cycle as calculated using the 
Watson Pragmatic model in the 
FlowJo cell cycle platform.  Data 
acquired on FACS Vantage with 
DiVa software (BD Biosciences).  
Significance was established using 
the unpaired student t test (Prism 4 
(GraphPad Software, San Diego, 
CA, USA)). ***p<0.0001, 
**p<0.001, *p<0.01, and 
+++p<0.0005.  (mean ± SEM, 
n≥3). 
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Since SHIP has been shown to negatively regulate proliferation of different 
cell types,18 its deficiency could lead to an increase HSC cell cycle activity.  In 
agreement with this, we observed that SHIP-/- BM contained a greater proportion 
of KTLS in the S/G2 phase, 23.2±1.5% as compared with 14.1±0.1% for WT BM 
(Figure 5C).  This study directly demonstrates that SHIP-/- HSC themselves have 
increased cycling activity relative to WT.  This is consistent with findings of 
Helgason et al that CRU in SHIP-/- BM are more sensitive to 5-fluorouracil 
treatment.156   In SHIPP-/- BM, we also observed a significant decrease in the 
proportion of HSC in the quiescent (G0/G1) stage: a subset of cells enriched for 
long-term multi-lineage engraftment relative to those that have entered the cell 
cycle.147,165-167 
 
Induced Deletion of SHIP During Adulthood Leads to an Increase in KFLS 
Numbers in Hematopoietic Organs 
 
 
In the previous section, we studied the impact of SHIP ablation in germline 
knockout mice.  Although this model is very useful, SHIP is ablated during 
embryogenesis, which could lead to the disruption of cell function or signaling 
pathways necessary for normal development.  Thus, we also assessed the levels 
of HSC in an inducible Mx1-Cre-loxP SHIP knockout model, where SHIP is 
deleted only during adulthood, allowing for the mice to develop normally.  In this 
model, the region to be targeted is flanked by loxP sites, and the Cre expression 
is under the control of the Type 1 interferon-inducible Mx1 promoter.43,102,103  
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Treatment of these mice with a double stranded RNA homolog, polyinositolic 
polycytidylic acid (polyIC), leads to the induction of an endogenous anti-viral 
Type 1 interferon response, which results in Mx1 promoted Cre expression and 
Cre-mediated recombination of the target gene, in this case the SHIP promoter 
and first exon.102,103.  This deletion results in the ablation of SHIP expression.  
Twenty-one days after polyIC treatment, the mice were euthanatized and HSC 
were quantitated by flow cytometry (Figure 6).  As a negative control, we used 
MxCre- mice treated with polyIC, however, since the MxCre promoter/gene is 
missing, no rearrangement of the loxP site can take place.  In the three 
hematopoietic organs examined, BM, PB and spleen, we observed a significant 
increase in the percentage of KFLS cells in MxCre+fl/fl mice as compared to 
MxCre-fl/fl.  In the BM of SHIP-ablated mice, we observed a subtle but statistically 
significant increase of 1.5-fold in the percentage and absolute number of KFLS 
cells as compared to MxCre- mice (Figure 6 a, b).  Interestingly, the spleen and 
the PB of SHIP-ablated mice exhibited the greatest increase in the percentage of 
KFLS cells.  Indeed, there was a 9.8 and 16.7-fold increase, respectively, in the 
percentage and in the absolute numbers of KFLS cells in SHIP-ablated spleen as 
compared to control (Figure 6 b).  In the PB of SHIP-ablated mice, we observed 
a 12.6-fold increase in the percentage of KFLS cells (Figure 6 b).  This result is 
consistent with these two organs being more dynamic than the BM, and 
therefore, responding more rapidly to the absence of SHIP.  Furthermore, in 
another experiment, we determined that the percentage and absolute number of 
KLSCD48- cells were significantly increased 3.2-fold and 5.6-fold, respectively, in 
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SHIP-ablated BM.  In these same mice, we observed a 3.9-fold augmentation in 
KLSCD48- cells in the PB.  KLSCD48- cells were not increased to the same 
levels than KFLS in the PB, this might result from the fact that CD48 appears to 
be present on cycling HSC.168  Since most of the HSC that are mobilized to the 
PB usually are proliferating, it is difficult to find the KLSCD48- cells in the PB.  
Nevertheless, we observed that SHIP ablation during adulthood results in an 
enlargement of the HSC compartment, suggesting that the HSC increase 
observed in SHIP-/- germline mice is not the result of a developmental defect.  
These results also suggest that the effect of SHIP ablation on the HSC 
compartment is intrinsic to the HSC. 
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Figure 6.  Significant increase in the percentage and absolute number of HSC in SHIP-
ablated BM, spleen and PB.  MxCre+ and MxCre- mice with floxed SHIP alleles were 
treated 3 times with 625 μg of polyIC in the course of a week, 21 days prior to being 
analyzed.  (A) Representative FACS plots showing detection of KFLS HSC in SHIP-
ablated and MxCre- BM.  (B)  Percentage of KFLS cells in the BM, spleen and PB of 
SHIP-ablated (black) and MxCre- (grey) mice, and absolute number of KFLS cells in BM 
(per femur and tibia pair) and spleen.  (C) Representative FACS plots showing detection 
of KLSCD48- HSC in SHIP-ablated and MxCre- BM. (D) Percentage of KLSCD48- cells 
in the BM and PB of SHIP-ablated (black) and MxCre- (grey) mice, and absolute number 
of KLSCD48- cells in BM (per femur and tibia pair).  Data acquired on a FACS Calibur 
with CellQuest software (BD Biosciences), analyzed with FlowJo.  Significance was 
established using the unpaired student t test (Prism 4). *p<0.01, ++ p<0.005, and 
+p<0.05.  (mean ± SEM, n≥3). 
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SHIP-/- BM Cells Show Decreased Ability to Reconstitute the Hematopoietic 
Compartment of Lethally Irradiated Recipients 
 
It was previously reported that SHIP-/- BM cells have a lower ability to 
reconstitute irradiated mice after transplantation, but contains similar CRU 
activity as compared to WT BM when measured by limiting-dilution assay.156  
Since these results are inconsistent with our finding that SHIP-/- BM contains 
increased number of HSC (Table 1, Figure 5), we addressed this discrepancy by 
measuring the ability of SHIP-/- HSC to accomplish long-term multi-lineage 
repopulating activity.  We first performed a well-defined CRU assay as described 
by Harrison169 to assess the level of repopulation activity in WBM.  WBM is used 
for the CRU assay and therefore is not dependent on isolation of HSC based on 
cell surface markers, whose expression can be altered by genetic mutation of 
unrelated loci.170  Using this assay, we observed that SHIP-/- BM cells did not 
reconstitute recipients as efficiently as WT littermates, with a significant reduction 
of 4.4-fold in CRU numbers in primary transplant recipients (Figure 7A, B). 
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Figure 7.  SHIP-/- WBM cells have compromised reconstituting activity.  (A) CRU activity 
calculated based on the percentage of 
global repopulation in the PB by donor 
WBM cells (SHIP-/- (black); WT (grey)).  (B) 
Percentage of global repopulation of PB by 
SHIP-/- (black) and WT (grey) donor in a 
CRU assay.  (C) Percentage of lymphoid 
and myeloid PB cells derived from SHIP-/- 
(black) or WT (grey) WBM 16 weeks after 
transplantation in a CRU assay.  Data 
acquired using FACS Calibur, CellQuest 
software (BD Biosciences) and analysis 
done with FlowJo.  Significance was established using the unpaired student t test (Prism 
4): ***p<0.0001, **p<0.001, and +p<0.05.  (mean ± SEM). 
 
SHIP-/- BM cells showed a significant decrease in long-term reconstitution 
of both the lymphoid and myeloid cell lineages.  For example, 16 weeks after 
transplantation only 13.2±2.7% of B cells were SHIP-/- derived (CD45.2+) 
compared to 60.1±2.8% for WT (CD45.1+) WBM, T cell repopulation were 
21.2±4.7% SHIP-/- derived vs. 39.7±4.1 for WT and 34.7±5.2% of myeloid cells 
were SHIP-/- BM derived vs. 57.4±2.8% from WT (Figure 7C).  The reduction in 
the SHIP-/- B cell representation observed in the CRU assay agrees with other 
studies showing that SHIP deficiency negatively impacts early B-lineage 
development.171  We did not observe that SHIP-/- BM cells had enhanced myeloid 
repopulation relative to WT BM cells (Figure 7C).  However, we did observe a 
bias toward myeloid differentiation within cells derived from SHIP-/- BM, where 
59.7±2.7% of the CD45.2+ in the SHIP-/- WBM recipients were Mac1+/Gr1+ 
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compared to 24.1±2% for WT BM recipients.  This occurred at the expense of the 
B cell lineage, for which only 25.3±1.5% of CD45.2+ cells were B220+ compared 
to 61.8±3.1% for WT (data not shown).  The overall reduction in long-term multi-
lineage repopulation by SHIP-/- BM cells demonstrates that despite the increase 
in HSC numbers observed (Table 1 and Figure 5A, B), HSC activity is 
significantly compromised in these mice (Figure 7A, C). 
 
 
Measuring HSC activity by transplantation of WBM from mutant mice can 
be confounded by the fact that the mutation can endow lineage-committed 
progenitor cells with properties that may obscure the observation of 
compromised HSC function.172  This is a concern when working with SHIP-/- BM 
as the SHIP mutation enhances myelopoiesis, causing an increase in myeloid 
progenitors, which have enhanced survival.95  Therefore, analysis of HSC activity 
in SHIP-/- mice must also be assessed with purified HSC to rule out these 
potential experimental artifacts.  To directly assess whether SHIP expression by 
HSC is required for long-term multi-lineage repopulation and self-renewal, we 
directly compared the repopulating potential of purified HSC from SHIP-/- and WT 
mice.  Thus, CD45.2 SHIP-/- KTLS or KFLS cells were transplanted into lethally 
irradiated CD45.1/CD45.2 WT recipients with an equivalent number of CD45.1 
WT KTLS or KFLS and Sca1- CD45.1/CD45.2 support cells.  This assay, the 
direct competition (DC) assay,173 directly compares the capacity of genetically-
modified HSC to compete with WT HSC for engraftment and long-term multi-
lineage repopulation. The level of repopulation in recipients PB was assessed at 
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regular intervals (Figure 8A), and at sixteen to twenty weeks post-transplant, we 
observed that global repopulation by SHIP-/- KTLS was reduced by 15-fold 
relative to WT KTLS (Figure 8B). 
 
Figure 8.  SHIP-/- purified HSC have compromised reconstituting activity.  (A) FACS plots 
show the level of PB reconstitution 16-weeks after KTLS transplantation in a 
representative DC assay mouse using sorted SHIP-/- and WT KTLS.  (B) Percentage of 
global reconstitution 16 weeks after transplantation 
of sorted KTLS (SHIP-/- (black) and WT (grey)) 
(n=11 over 2 different experiments).  (C) Proportion 
of lymphoid and myeloid PB cells derived from 
SHIP-/- (black) or WT (grey) WBM 16-weeks after 
KTLS transplantation.  (D) Percentage of global 
reconstitution 12 weeks after sorted KFLS 
transplantation (SHIP-/- (black); WT (grey)) (n=7).  
Data acquired using FACS Calibur, CellQuest 
software (BD Biosciences) and analysis done with 
FlowJo.  Significance was established using the 
unpaired student t test (Prism 4): *p<0.01, 
++p<0.005 and +p<0.05.  (mean ± SEM). 
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Reconstitution of different lineage by SHIP-/- KTLS was also significantly 
reduced (Figure 8C).  Thus, SHIP-/- KTLS are capable of multi-lineage 
reconstitution, but are unable to sustain this activity for extended periods when in 
direct competition with WT KTLS (Figure 8C).  Furthermore, SHIP-/- cells did not 
dominate the myeloid compartment as might have been expected from previous 
studies,95,156 with only 1% of Mac1+/Gr1+ cells being derived from SHIP-/- KTLS 
vs. 21% from WT KTLS (Figure 8C).  This indicates that although SHIP-/- myeloid 
lineage progenitors have enhanced survival and can prevail over serially-
transplanted competitors,95,156 they are, nonetheless, unable to out-compete 
normal WT myeloid progenitors when derived from purified HSC in a chimeric 
transplant setting.  As with KTLS cells, long-term global repopulation by SHIP-/- 
KFLS is significantly reduced (Figure 8D).  These results demonstrate that SHIP 
expression is required by HSC in order to sustain long-term multi-lineage 
repopulation. 
 
SHIP-/- HSC do not Exhibit Characteristics of Premature Differentiation 
 
 
As HSC go down the path of differentiation, they lose the ability to self-
renew and exhibit a higher proliferative state.  Since we observed that SHIP-/- 
HSC proliferation is increased and engraftment is perturbed, we assessed by 
flow cytometry if SHIP-/- KTLS exhibited immunophenotypic characteristic of early 
differentiation.  It has been shown that KTLS cells with high levels of c-Kit (c-Kithi) 
are enriched for LT-HSC activity, as opposed to the c-Kitlo population that is not 
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able to support long-term multi-lineage repopulation.174  This assay revealed that 
a significantly greater proportion of SHIP-/- TLS were c-Kithi as compared to WT 
KTLS cells (Figure 9A, B).  There was a greater than 3 fold increase in the 
percentage of c-KithiTLS in the SHIP-/- BM as compared to WT BM (Figure B). 
 
 
Figure 9.  More SHIP-/- TLS cells express high levels of c-Kit as compared to WT.  (A) 
Representative FACS plots showing detection of Lin-Thy1+Sca1+c-Kithigh and Lin-
Thy1+Sca1+c-Kitlow.  (B) Percentage (left column) and absolute number (right column) of 
Lin-Thy1+Sca1+c-Kithigh (top row) and Lin-Thy+Sca1+c-Kitlow cells).  Absolute numbers 
calculated for 1 pair of femur and tibia.  Data acquired on a FACS Aria with DiVa 
software, analyzed with FlowJo.  Significance was established using the unpaired 
student t test (Prism 4). ***p<0.0001 and ++p<0.005.  (mean ± SEM, n=4). 
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In fact, in SHIP-/- mice 95% of KTLS cells expressed high levels of c-Kit 
while only 78% of KTLS in WT mice (Figure 9A).  This analysis revealed that the 
percentage and the mean absolute number of c-KithiTLS cells in SHIP-/- WBM 
cells were 4 and 4.6 fold higher, respectively, as compared to WT littermates 
(Figure 9B).  As LT-HSC differentiate towards short term (ST)-HSC phenotype, 
they begin expressing increasing amount of Mac-1 on their surface, they 
proliferate at a faster rate and have a reduced ability to self-renew.159  Therefore, 
we assessed the level Mac1 expression on SHIP-/- KTLS cells in order to better 
characterize the HSC compartment in these mice.  After gating on live KTLS 
cells, we looked at the level of Mac1 expression on SHIP-/- and WT HSC by flow 
cytometry.  Since the histogram for Mac1 on KTLS was unimodal, we assessed 
the level of Mac1 expression using the mean fluorescence intensity (MFI) instead 
of percentages (Figure 10A, B).  Our results revealed that SHIP-/- KTLS cells 
express comparable levels of Mac1 molecules on their surface as WT KTLS 
(Figure 10A, B), suggesting that the proportion of ST-HSC contained in SHIP-/- 
KTLS fraction is not increased as compared to WT control.  Thus, according to 
this phenotypic assay, SHIP-/- KTLS do not exhibit characteristic of premature 
differentiation. 
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Figure 10.  SHIP-/- KTLS express similar levels of Mac1 as compared to WT KTLS.  (A) 
Representative FACS plots showing detection of Mac1 expression (histogram) on KTLS.  
(B) Two representative overlay histogram of Mac1 expression for SHIP-/- (black) and WT 
(grey) KTLS. (C) Graph comparing the MFI of Mac1 expression for SHIP-/- and WT 
KTLS.  Data acquired on a FACS Aria with DiVa software, analyzed with FlowJo.  
Statistical analysis was done using the unpaired student t test (Prism 4).  (mean ± SEM, 
n=4). 
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SHIP-/- HSC Self-Renew to a Lesser Extent than WT HSC in Transplanted Mice 
 
Our data suggest that SHIP-deficient mice have increase in HSC number 
and proliferation.  However, once transplanted these cells did not reconstitute the 
host was well as WT HSC.  One of the hypothesis proposed to explain these 
observation was that SHIP-/- HSC might be unable to differentiate.  In that case, 
SHIP-/- HSC would be present in the BM and self-renew without having the ability 
to differentiate and reconstitute the host PB.  Therefore, we assessed the level of 
reconstitution of the different hematopoietic organs of transplanted mice at least 
6 months after transplantation.  Three of the CRU transplanted mice were 
sacrificed and their spleen, BM and PB were assessed for 
granulocyte/macrophage and lymphoid reconstitution.  This assay revealed that 
every lineage in every organ except for Mac1Gr1 in PB was significantly less 
reconstituted by SHIPP-/- WBM cells as compared to WT WBM cells (Figure 11A).  
The majority of the lineages were reconstituted to less than 25% by SHIP-/- WBM 
cells. 
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Figure 11.  SHIP-/- HSC do not engraft and self-renew as well as WT HSC, although 
transplanted in equal numbers.  (A) CD45.1 mice were irradiated (1000 rads) and 
transplanted with 1 million CD45.2 SHIP-/- and 1 million CD45.1 WT WBM.  Percentage 
of lymphoid and myeloid PB, spleen and BM cells derived from SHIP-/- (black) or WT 
(grey) WBM >16 weeks after transplantation.  (B) Percentage of KTLS cells in the BM 
that are derived from SHIP-/- (black) or WT (grey) WBM.  (C) CD45.1xCD45.2 mice were 
irradiated (600 and 400 rads at 3-hour interval) and transplanted with 2x105 CD45.2 
SHIP-/- and 2x105 CD45.1 WT KTLS cells with 4x105 CD45.1xCD45.2 Sca1- cells.  First 
bar graph shows the percentage of KTLS cells derived from SHIP P-/- (black) or WT (grey) 
KTLS cells.  Second bar graph Absolute numbers of SHIP-/- and WT KTLS found in 1 
pair of femur and tibia SHIP-/- (black) or WT (grey) KTLS cells.  Third bar graph 
compares fold expansion for SHIP-/- and WT KTLS cells SHIP-/- (black) or WT (grey) 
KTLS cells.  Data acquired using FACS Vantage, DiVa software and analysis done with 
FlowJo.  Significance was established using the unpaired student t test (Prism 4): 
*p<0.01, +++p<0.0005, ++p<0.005 and +p<0.05.  (mean ± SEM, n=3) 
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We then had to consider that the SHIP-/- HSC could self-renew but not 
differentiate as efficiently as WT.  Thus, we observed the level of reconstitution of 
the KTLS compartment.  Briefly, BM cells were enriched for HSC by lineage 
depletion using the AutoMACS (Miltenyi Biotec, Auburn, CA, USA), and then 
stained for KTLS, CD45.1 and CD45.2 in the presence of DAPI.  This assay 
revealed that the percentage of KTLSCD45.2+ (SHIP-/-) over the total amount of 
KTLS cells was 13.8 ± 4.8%, while 57.3 ± 7.2% of KTLS were CD45.1+ (WT) 
(Figure 11B).  Therefore, the capacity of SHIP-/- WBM cells to reconstitute the 
HSC compartment of a transplanted mouse is significantly lower than he one of 
WT WBM cells, p=0.007 (Figure 11B).  This result correlates with the lower 
reconstitution of the different hematopoietic organs by SHIP-/- CD45.2 cells 
(Figure 11A).  In the CRU assay the recipient is CD45.1, therefore, we could not 
totally exclude that a portion of CD45.1+ KTLS came from the host.  To address 
this issue, we assessed the level of KTLS reconstitution in DCA transplanted 
mice more than 12 months after transplantation.  In this case the recipients are 
CD45.1xCD45.2, thus WT (CD45.1) and SHIP-/- (CD45.2) cells can be 
differentiated from the host.  In these transplanted mice, it was also obvious that 
CD45.2 SHIP-/- KTLS cells composed a significantly reduced portion of the KTLS 
compartment as compared to WT (Figure 11Ci).  The absolute numbers of SHIP-
/- KTLS cells contained in one hind limb were reduced 6.4-fold as compared to 
the number of WT KTLS (Figure 11Cii).  Furthermore, the fold expansion of 
KTLS cells calculated based on the amount of transplanted KTLS cells and the 
total amount of KTLS recovered in the recipients revealed that SHIP-/- KTLS only 
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expanded 44 ± 25-fold compared to 287 ± 56 fold for WT KTLS.  Thus, SHIP-/- 
KTLS did no self-renew with the same efficiency than WT KTLS p=0.008 (Figure 
11Ciii).  These results confirm that SHIP-/- WBM and KTLS cells cannot 
reconstitute the hematopoietic system of a lethally irradiated mouse as efficiently 
as WT cells.  The higher proliferative profile of SHIP-/- HSC should have given 
them an advantage in the reconstitution assay.  Therefore, we had to further 
investigate why SHIP-/- HSC are not able to accomplish long-term reconstitution. 
 
SHIP-/- HSC Have a Lower Rate of Spontaneous Apoptosis 
 
It was reported that SHIP-/- mice have increased osteoporosis caused by 
an increase in osteoclast activity.101  The HSC niche is dependent on the 
presence of osteoblasts, the counter part of osteoclasts, to properly sustain the 
hematopoietic compartment.132  Thus, any disruption of the balance between 
osteoblasts and osteoclasts could destroy the niche necessary for HSC survival, 
resulting in anoikis-associated apoptosis of the HSC compartment.  If SHIP-/- 
HSC exhibited increased apoptosis, this could contribute to the decreased ability 
of SHIP-/- HSC to accomplish long-term repopulation.  Therefore, we assessed 
the level of apoptosis in SHIP-deficient HSC and we found that a significantly 
lower proportion of SHIP-/- HSC were apoptotic relative to WT HSC as measured 
by Annexin V staining (Figure 12A).  In fact, 11.1% of WT HSC (KTLSFlk2-) 
stained with Annexin V while only 1.1% of SHIP-/- HSC did.  TUNEL analysis 
 
46 
  
done on SHIPΔIP/ΔIP HSC also revealed that SHIP-deficient HSC were undergoing 
apoptosis at half the rate of WT HSC in the BM (Figure 12B).  Thus, the lack of 
long-term repopulating activity of SHIP-/- HSC activity appears not to be 
associated with anoikis-induced apoptosis of the compartment. 
 
 
Figure 12.  SHIP-/- HSC exhibit decreased apoptotic rate.  (A) Representative FACS 
plots of DAPI vs. Annexin V after gating on KTLSFlk2- cells.  Bar graph shows the 
percentage of KTLSFlk2- that are apoptotic based on the Annexin V+ and DAPI- staining, 
SHIP-/- (black); WT (grey).  (B) Representative FACS plots for TUNEL staining after 
gating on KTLS cells.  Bar graph represents the percentage of KTLS cells positive for 
TUNEL staining, SHIP-/- (black); WT (grey).  Data acquired using FACS Aria, DiVaII 
software and analysis done with FlowJo.  Significance was established using the 
unpaired student t test (Prism 4): *p<0.01 and ++p<0.005. (mean ± SEM, n≥3). 
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In vivo Homing of SHIP-/- Stem/Progenitors to the BM is Significantly Reduced as 
Compared to WT 
 
We considered that the diminished repopulation observed for SHIP-/- HSC 
could result from an inefficiency of SHIP-/- HSC to home and be retained in the 
BM niche.  Thus, we assessed the homing capacity of SHIP-/- stem/progenitor 
cells compared to WT cells in an in vivo homing assay.147,175  Sca1+Lin- cells from 
the BM of SHIP-/- and WT mice were isolated, stained with fluorescent dyes, and 
injected into irradiated recipient mice.  The frequency of SHIP-/- and WT 
Sca1+Lin- cells present in the recipient BM and spleen was later assessed by 
flow cytometry (Figure 13A).  Using a total of 12 recipients for each genotype, we 
found that SHIP-/- stem/progenitor cells reached the BM with a significantly 
reduced efficiency relative to WT stem/progenitor cells (Figure 13B).  
Furthermore, we observed that SHIP-/- Sca1+Lin- cells did not home to the spleen 
as well as WT Sca1+Lin- cells (Figure 13C).  These results suggest that SHIP-/- 
HSC are impaired in their ability to home and be retained in hematopoietic 
organs.  This deficiency likely contributes to their inability to engraft and sustain 
multi-lineage hematopoiesis. 
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Figure 13.  SHIP-/- Sca1+Lin- cells do not home to the BM as efficiently as WT Sca1+Lin-.  
(A) Representative FACS plot of BM from 
transplant recipients after gating on live 
cells.  (I) Shows BM from control recipient 
12-14 hours after transplantation with 
0.5x106 WBM stained with 1 μM DDAO .  
(II) Shows BM from control recipient 12-14 
hours after transplantation with 0.5x106 
WBM stained with 0.5 μM CFSE. (III) 
Representative FACS plot of BM from a 
mouse 12-14 hours after transplantation 
with 2x105 SHIP-/- Lin-Sca1+ cells stained 
with 0.5 μM CFSE and 2x105 WT Lin-Sca1+ 
cells stained with 1 μM DDAO. (B) Left: 
Percentage of dye+ SHIP-/- (black) or WT 
(grey) Sca1+Lin- cells found in the recipient 
BM 12-14 hours after transplantation. Right: 
Percentage of SHIP-/- (black) or WT (grey) 
Sca1+Lin- cells that trafficked to and was 
retained in BM of recipients over the total 
number of cells injected, 12-14 hours after 
transplantation.  (C) Left: Percentage of 
stained SHIP-/- (black) or WT (grey) 
Sca1+Lin- cells found in the spleen of recipients 12-14 hours after transplantation.  Right: 
Percentage of SHIP-/- (black) or WT (grey) Sca1+Lin-cells that reached the spleen of 
recipients over the total number of cells injected, 12-14 hours after transplantation.  Data 
acquired using FACS ARIA, DiVaII and analysis done with FlowJo.  Significance was 
established using the stratified Wilcoxon-Mann Whitney test using StatXact (Cytel 
Software Corporation, Cambridge, MA, USA): +p<0.05, *p<0.01 and ++p<0.005.  (mean 
± SEM, n=12). 
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Reduced Surface Expression of CXCR4 and VCAM-1+ on KTLS Cells in SHIP-/- 
BM 
 
 
CXCR4, VCAM-1 and VLA-4 are all known to play prominent roles in 
homing and trafficking of HSC and other hematopoietic cells to BM.151,158,176  
Thus, we decided to examine the level of expression of these markers on SHIP-/- 
HSC cells compared to WT HSC.  By flow cytometry, we observed a 2.5-fold 
reduction in the surface expression of the CXCR4 receptor on SHIP-/- KTLS 
relative to WT KTLS (Figure 14A, B).  Flow cytometry analysis showed a 
reduction in VCAM-1 surface expression on SHIP-/- HSC cells as compared to 
WT HSC (Figure 14A).  We found that 22.1±2.5% of SHIP-/- KTLS were positive 
for VCAM-1 while 50.8±6.9% of WT KTLS were (Figure 14A, B).  The VCAM-1 
MFI values for SHIP-/- KTLS were also reduced by 3-fold as compared to WT 
KTLS (Figure 14B).  However, not all homing molecules showed a reduced level 
of expression.  For example, the percentage of KTLS cells expressing VLA-4 as 
well as their MFI values in SHIP-/- BM cells were unchanged compared to WT 
BM.  Furthermore, contrary to SHIP-/- KTLS, SHIP-/- Lin+c-Kit- and Lin-c-Kit+ cells 
did not exhibit a significant difference in the level of VCAM-1 and CXCR4 
expression as compared to WT Lin+c-Kit- cells (Figure 15).  We also observed 
the level of VCAM-1 and CXCR4 expression in the KLS and KLSThy1- 
populations to evaluate if SHIP deficiency impacted the expression of these 
markers in different progenitor population or only in the HSC enriched KTLS 
population.  We observed that the reduction in CXCR-4 expression is specific to 
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the KTLS population (Figure 14).  The KLS population, which contains HSC and 
mostly early and late progenitor cells did not exhibit a significant difference in 
their ability to express CXCR4 in the absence of SHIP as compared to WT 
controls (Figure 16Bi-Ci).  Furthermore, we observed no significant difference in 
the level of CXCR4 expression by SHIP-/- KLSThy1- cells as compared to WT 
control (Figure 17Bi-Ci).  However, percentage of VCAM-1+ KTL (Figure 16Cii) 
and KLSThy1- (Figure 17Cii) were both reduced by 2-fold in SHIP-/- mice BM as 
compared to WT control.  These results suggest that SHIP might impact VCAM-1 
expression in different cell types, including KTLS (Figure 14), KLS (Figure 16), 
and KLSThy1- cells (Figure 17), while SHIP appears to affect CXCR4 expression 
mostly in KTLS cells (Figure 14 - 17).  Interestingly, the late progenitor cells (lin-
cKit+) and differentiated cells (Lin+cKit-) (Figure 15) in SHIP-/- mice had a 
comparable level of CXCR4 and VCAM-1 expression as compared to WT.  
Reduction of VCAM-1 and CXCR4 expression on the SHIP-/- HSC suggests 
these cells may be hampered in their ability to traffic and be retained in the BM, 
consistent with the decreased BM homing and retention we observe (Figure 13). 
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Figure 14.  SHIP-/- HSC express lower levels of CXCR4 and VCAM-1 molecules as 
assessed by flow cytometry.  (A) A representative histogram of CXCR4 (left) and VCAM-
1 (right) expression on live (DAPI-) KTLS cells (isotype control (light grey), SHIP-/- 
(black), and WT (grey)).  (B) The plots on the left represent the mean fluorescence 
intensity (MFI) of KTLS cells for CXCR4, VCAM-1, and VLA-4, respectively and the plots 
on the right show the percentage of KTLS cells positive for VCAM-1 and VLA-4, 
respectively (SHIP-/- (square); WT (triangle)).  Data acquired using FACS ARIA, DiVaII 
and analysis done with FlowJo.  Significance was established using the unpaired student 
t test (Prism 4): +++p<0.0005 and +p<0.05.  (mean ± SEM, n≥3). 
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Figure 15.  SHIP-/- late progenitor and differentiated cells express the same levels of 
homing molecules as assessed by flow cytometry.  (A) A representative histogram of 
CXCR4 (left) and VCAM-1 (right) expression on live (DAPI-) Lin+c-Kit- (isotype control 
(light grey), SHIP-/- (black), and WT (grey)).  (B) The plots on the left represent the mean 
fluorescence intensity (MFI) of Lin-c-Kit+ (top) and Lin+c-Kit- (bottom) cells for CXCR4, 
VCAM-1, and VLA-4, and the plots on the right show the percentage of Lin-c-Kit+ (top) 
and Lin+c-Kit- (bottom) cells positive for CXCR4, VCAM-1 and VLA-4.  (SHIP-/- (black); 
WT (grey)).  Data acquired using FACS ARIA, DiVaII and analysis done with FlowJo.  
Statistical analysis was done using the unpaired student t test (Prism 4).  (mean ± SEM, 
n≥3). 
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Figure 16.  SHIP-/- early progenitors express the same levels of CXCR4 and have a 
reduced percentage of VCAM-1+ cells.  (A)  FACS plot representing gating strategy for 
the analysis of CXCR4 and VCAM-1 expression on KLS cells for (i) SHIP-/- and (ii) WT 
BM cells. (B) A representative histogram of CXCR4 (i) and VCAM-1 (ii) expression on 
live (DAPI-) Lin-c-Kit+Sca1+ (isotype control (light grey), SHIP-/- (black), and WT (grey)).  
(C) (i) Bar graphs representing the percentage and MFI of Lin-c-Kit+Sca1+ cells for 
CXCR4 expression. (ii)  Bar graphs representing the percentage and MFI of Lin-c-
Kit+Sca1+ cells for VCAM-1 expression.  Data acquired using FACS ARIA, DiVaII and 
analysis done with FlowJo.  Statistical analysis was done using the unpaired student t 
test (Prism 4).  (mean ± SEM, n≥3). 
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Figure 17.  SHIP-/- early progenitors express the same levels of CXCR4 and have a 
reduced percentage of VCAM-1+ cells.  (A) FACS plot representing gating strategy for 
the analysis of CXCR4 and VCAM-1 expression on KLSThy1- cells for (i) SHIP-/- and (ii) 
WT BM cells.  (B) A representative histogram of CXCR4 (i) and VCAM-1 (ii) expression 
on live (DAPI-) Lin-c-Kit+Sca1+Thy1- (KLSThy1-) (isotype control (light grey), SHIPP-/- 
(black), and WT (grey)).  (C) (i) Bar graphs representing the percentage and MFI of Lin-
c-Kit+Sca1+ cells for CXCR4 expression. (ii)  Bar graphs representing the percentage 
and MFI of KLSThy1- cells for VCAM-1 expression.  Data acquired using FACS ARIA, 
DiVaII and analysis done with FlowJo.  Statistical analysis was done using the unpaired 
student t test (Prism 4).  (mean ± SEM, n≥3). 
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Elevated Levels of Soluble VCAM-1 Levels in SHIP-/- Mice Sera 
 
Interestingly, we observed that SHIP-/- mice sera contained an increased 
level of soluble VCAM-1 (sVCAM-1) (Figure 18).  This molecule once released in 
the circulation through proteolytic cleavage remains active and can still bind VLA-
4 receptor.177,178  Thus, sVCAM-1 has the potential to hinder the interaction of 
leukocyte and HSC with endothelium.179,180  Therefore, elevated sVCAM-1 could 
potentially bind VLA-4 receptor on HSC and prevent its interaction with 
endothelium-bound VCAM-1 and prevent its homing to the BM.  This particular 
scenario could in part explain why we see an increase in HSC number in the 
periphery and maybe why we see a decrease in the homing properties of these 
cells.  One theory for the latter hypothesis would be that sVCAM1 bind the VLA-4 
receptor, preventing their interaction with membrane-bound VCAM-1. 
 
Figure 18.  sVCAM-1 levels are significantly increased 
in SHIP-/- sera as compared to WT littermates.  Blood 
was obtained by sub-mandibular bleed and collected in 
regular Eppendorf tube to allow coagulation.  The sera 
was then collected and sent for analysis by ELISA 
(Charles River Laboratories Inc.).  ELISA was then 
performed to assess the level of different cytokines.  
Significance was established using the unpaired student t test (Prism 4): ++p<0.005 
(mean ± SEM, n≥3).  Collaboration with D. Woods and WG Kerr Ph.D. 
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Discussion 
 
In this study, we show that SHIP-/- mice had increased HSC in their BM, 
spleen and PB than WT littermates based on analysis using multiple HSC 
phenotypes.  An expansion of the HSC compartment was also observed in a 
second SHIP-deficient model, in which the inositol phosphatase region was 
targeted, the SHIPΔIP/ΔIP.97  This latter model is deficient for SHIP expression and, 
presumably s-SHIP expression, contrary to the SHIP-/- model.  s-SHIP is an 
isoform expressed in ES cells and HSC but not in differentiated cells.49  Our 
studies show that SHIPΔIP/ΔIP HSC have a similar phenotype to the SHIP-/- HSC 
as compared to WT showing an expansion of the HSC compartment, decreased 
apoptosis rate and decreased level of CXCR4 expression.  According to our 
data, the ablation of both isoforms did not result in a more severe HSC 
phenotype.  However, additional studies should be done to further assess the 
role of s-SHIP in this cell type. 
 
The increase in HSC numbers observed in SHIP-deficient mice may partly 
result from the increased proliferation and decreased apoptotic frequency 
observed in the SHIP-/- HSC compartment.  These results are consistent with 
SHIP being a negative regulator of several signaling pathways downstream of 
receptors that impact HSC proliferation and survival, such as c-mpl, IL-3R, 
CXCR4, Flt3 and c-Kit, which induce cell proliferation and/or survival through 
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activation of the MAPK and PI3K/Akt pathways.15,25,47,181-187  Moreover, SHIP-/- 
myeloid and hematopoietic progenitor cells are hyper-responsive to several of 
these factors.18  The enhanced survival and proliferation of SHIP-/- HSC could 
partially explain the decreased repopulating ability of these cells as it was shown 
that cycling HSC engraft less efficiently than resting HSC.146,165,167 
 
 
Homing and eventual engraftment of HSC following transplantation has 
been shown to rely on the expression and activity of several surface molecules, 
including VLA-4, VLA-5 and CXCR4.151,188,189  The CXCR4 receptor induces cell 
migration towards an increasing gradient of SDF-1/CXCL12.149  Treatment of 
NOD/SCID mice with SDF-1 leads to the mobilization of HSC to PB150 and 
treatment of human HSC with anti-CXCR4 antibody prior to transplantation in 
NOD/SCID mice results in HSC engraftment failure.151  Furthermore, CXCR4 and 
SDF-1-deficient mice are embryonic lethal since HSC fail to migrate from the FL 
to the BM, where definitive hematopoiesis would take place.  In addition, one of 
the ligands for VLA-4, VCAM-1, which is usually found on stromal/endothelial 
cells, has been shown to be expressed in hematopoietic cells such as Mac-1+, 
B220+ and, more interestingly, c-Kit+ cells.158  Even though the role of VCAM-1 
on hematopoietic stem/progenitor cells remains to be fully elucidated, there is 
evidence that it is involved in their retention in the BM, as shown for B cell 
progenitors.158  With that information in mind, the reduction in the percentage of 
HSC expressing CXCR4 and VCAM-1 receptors in SHIP-/- BM can provide a 
basis for the decrease in SHIP-/- HSC ability to home to the BM, as shown by our 
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in vivo homing assays (Figure 13).  This inefficiency of SHIP-/- HSC to reach and 
be retained in the HSC niche could contribute to their impaired self-renewal and 
long-term repopulating capacity.  In previous studies, in vitro stimulation of 
murine BM stem/progenitor cells with different cytokines was shown to induce 
cell cycle, decrease VLA-4 expression and compromise engraftment.146  In our 
study, the increase in HSC cell cycle observed in vivo did not necessarily 
correlate with a decrease in VLA-4 expression, but caused a decline in long-term 
engraftment capacity.  We observed that decreased CXCR4 and VCAM-1 
expression on KTLS cells correlated with a reduction in the homing process.  
Moreover, CXCR4 has been shown to participate in the activation of VLA-4 and 
VLA-5 to promote human HSC attachment and extravasation, resulting in homing 
of HSC to the BM niche.189  The reduction in the CXCR4 receptor seen on SHIP-/- 
HSC might also dampen this process and, thus, HSC homing.  Furthermore, it 
has been shown that CXCR4 and VCAM-1 are important for the retention of HSC 
or hematopoietic progenitors in the BM.157,158  Interestingly, we find that SHIP-/- 
mice have an increased number of HSC cells in their spleen (Table 1 and Figure 
5A, B) and peripheral blood (data not shown), consistent with the down 
modulation of CXCR4 and VCAM-1 on SHIP-/- HSC.  On the other hand, the 
increased level of sVCAM-1 in the plasma of SHIP-/- mice could hinder the 
interaction between HSC and endothelium and dampen the homing and retention 
process of these cells. 
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Even though we observed a reduction in engraftment by both the DC and 
CRU assay, the defect seems greater in the DC assay, where equal numbers of 
purified SHIP-/- and WT HSC are co-transplanted.  This suggests that in the CRU 
assay, where WBM cells are used, the increased number of HSC in SHIP-/- BM 
might partially compensate for the reduced levels of CXCR4 and VCAM-1 on 
SHIP-/- HSC, resulting in better engraftment by SHIP-/- HSC in the CRU assay as 
compared to the DC assay. 
 
The CRU assay included in this study showed a decrease in the 
repopulating ability of SHIP-/- WBM, while previous studies revealed that SHIP-/- 
WBM had comparable repopulating activity in a limiting-dilution CRU assay.156  
The different results observed between the two CRUs might stem from the 
variation in the assays themselves.  In the Harrison CRU assay, healthy 
competitor cells are utilized, while the limiting-dilution CRU assay requires the 
use of competitor WBM weakened by two serial transplantations.190  Thus, the 
compromised WBM competitors in the latter CRU assay may be unable to 
compete for the niche as efficiently as normal WT WBM against SHIP-/- WBM.  
Furthermore, the calculation method for the Harrison CRU assay differs from the 
one used for the limiting-dilution assay, which might result in a different 
assessment of repopulating activity by the two assays. 
 
 
In summary, our findings demonstrate a role for SHIP in the maintenance 
of the HSC compartment.  SHIP appears to be critical for the negative control of 
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HSC proliferation and survival as well as impacting the ability of HSC to home 
and be retained in the BM niche. 
 
Materials and Methods 
 
Mice 
 
SHIP-/- mice were generated by deletion of the promoter and first exon of 
SHIP via a Cre-loxP strategy and then backcrossed to the C57BL6/J 
background.43  SHIPPΔIP/ΔIP mice were created using a Cre-loxP strategy targeting 
the inositol phosphatase encoding region.  SHIPΔIP/ΔIP mice are on a 129SvJ 
background and were kindly provided by Dr. Jeffrey Ravetch (Rockefeller 
University, NY, USA).97  For all experiments, germline SHIP-deficient and WT 
mice were 6-8 weeks of age.  For the inducible model, SHIP fl/fl mice were 
backcrossed to MxCre germline.  The resulting SHIP fl/fl MxCre+ and MxCre- 
mice were treated 3 times with 625 μg polyIC in the course of 7 days.  At least 20 
days after the last treatment, the mice were sacrificed and experiment was 
performed.  As recipients for transplantation experiments we used 8-12 weeks 
old B6.SJL-Ptprca Pep3b/BoyJ (CD45.1) (Jackson Laboratory Bar Harbor, 
Maine, USA) and a CD45.1xCD45.2 strain generated by intercrossing C57BL6/J 
(CD45.2) and B6.SJL-Ptprca Pep3b/BoyJ (CD45.1) mice.  Animal experiments 
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were conducted in compliance with institutional guidelines at the University of 
South Florida. 
 
Cell Isolation 
 
BM cells were flushed from intact femurs and tibia.  Splenocytes were 
isolated by crushing the spleen with a syringe plunger.  All cells were collected in 
tissue media (TM) composed of RPMI, 3% fetal bovine serum (FBS), and 10mM 
HEPES (Gibco BRL/Invitrogen, Carlsbad, CA, USA).  Cells were then filtered 
through a 70μm strainer (BD Biosciences, San Jose, CA) and red blood cells 
(RBC) were lysed at room temperature (RT) for 2-5 minutes in 1xRBC lysis buffer 
(eBioscience, San Diego, Ca, USA).  The remaining cells were then centrifuged 
and resuspended in staining media (SM) composed of 1xDulbecco-Phosphate 
buffered saline (D-PBS), 3% FBS, and 10mM HEPES (Gibco BRL/Invitrogen).  
PB was obtained by retro-orbital (RO) or sub-mandibular bleeding, collected in 
microtainers with K2EDTA (BD, Franklin Lakes, NJ, USA), and RBC lysed twice 
to obtain PB mononuclear cells (PBMC), which were resuspended in SM. 
 
HSC Phenotype 
 
All antibodies were from BD Biosciences except where noted.  All flow 
cytometry data were analyzed with FlowJo Software (Tree Star, Inc. Ashland, 
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OR, USA).  BM cells, splenocytes or PBMC were treated with Fc block (2.4G2) 
and then stained on ice for Lineage-/lowc-Kit+Sca1+Thy1+ (KTLS) phenotype.159  
The stain included, Sca1-PE (E13-161.7), c-Kit-APC (2B8), Thy1.2-Cychrome 
(53-1.2) and a lineage (Lin) panel-FITC: CD2(RM2-5), CD3ε (145-2C11), 
CD4(GK1.5), CD5(53-7.3), CD8α(53-6.7), B220(RA3-6B2), Gr-1(RB6-8C5), Mac-
1(M1/70), NK1.1(PK136), and Ter119(TER-119) (eBioscience).  For Lin-c-
kit+Sca1+CD48-CD150+ (KLSCD48-CD150+),162 the same Lin panel was used 
with the addition of CD34–FITC (RAM34) along with Sca1-biotin (E13-161.7), c-
Kit-APCCy7 (2B8) (eBioscience), CD48-PE (HM48-1), CD150-Alexa647 (9D1) 
(Serotec Inc., Raleigh, NC, USA), followed with streptavidin-PeCy7.  The cells 
were then resuspended in SM containing 75ng/ml of 4',6-diamidino-2-
phenylindole dihydrochloride (DAPI) for dead cell exclusion (Sigma-Aldrich, 
St.Louis, MO, USA).  Analysis was done on a FACS Vantage or FACS Aria using 
DiVaII software (BD Biosciences).  For the c-Kit+Flk2-Lin-/lowSca1+ (KFLS) 
phenotype,160 we used Sca1-FITC, c-Kit-APC and the above mentioned Lin 
panel-PE with the addition of the Flk2 antibody (A2F.10-1).  After staining, the 
cells were washed and resuspended in SM containing 7-amino-actinomycin D (7-
AAD) (BD Biosciences) for dead cell exclusion.  Acquisition was done on a FACS 
Calibur with CellQuest software (BD Biosciences).  For the side population (SP) 
analysis, BM cells were stained following standard procedure.163  Analysis was 
done on a FACS Vantage using DiVaII.  For the analysis of Mac 1 expression on 
KTLS, the same Lin panel (FITC) as the one defined above was used with the 
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exception of Mac1.  The same antibody clones as the one mentioned above were 
used, but they were conjugated to different fluorochromes: Sca1-PE, c-Kit-
PeCy7, Thy-APC, Ma1-ApcCy7.  DAPI was used for dead cell exclusion and the 
data acquired on FACS Aria with DiVaII software. 
 
For homing marker analysis, Lin-depletion of BM cells was done on the 
AutoMACS (Miltenyi Biotec) using the Lin-PE panel described above, with the 
exclusion of CD2, anti-PE magnetic beads (Miltenyi Biotec).  The Lin-depleted 
fraction was stained for KTLS and CXCR4 (2B11/CXCR4), VCAM-1 (429), or 
VLA-4 (9C10) on biotin, followed by staining with streptavidin-PeCy7.  DAPI was 
used for dead cell exclusion.  Data was acquired on a FACS Aria using DiVaII. 
 
Cell Cycle Analysis 
 
BM cells were enriched either for Sca1+ or c-Kit+ cells using AutoMACS 
(Miltenyi Biotec).  Sca1+ or c-Kit+ cells were then stained for the KTLS or KFLS, 
then fixed in Cytofix/Cytoperm solution (BD Biosciences) for 30-min on ice, 
washed in Perm/Wash buffer and incubated with 4-10ng/ml Hoechst dye 33342 
(Sigma-Aldrich) in Perm/Wash buffer overnight at 4oC.  The DNA content was 
measured 24-hrs later on the FACS Vantage and analyzed using FlowJo 
software. 
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CRU Assay 
 
CD45.1 recipient mice were given antibiotic water -- sulfamethaxazole and 
trimethorprim oral suspension 40mg/ml (Hi-Tech Pharmacal CO., INC. Amityville, 
NY, USA) prior to receiving a single dose of 9.5-Gy 3-hours before 
transplantation.  One million WBM cells from CD45.2 SHIP-/- or WT mice along 
with 1x106 CD45.1 WBM cells were injected retro-orbitally into recipients, as per 
Harrison.169  Transplanted mice were later assessed for PB multi-lineage 
reconstitution.  Repopulating units (RU) were calculated as per Harrison et al.:169 
RU =  (10 * CD45.2 repopulation(%))/(100 – CD45.2 repopulation(%)).169 
 
DC Assay 
 
The DC assay was modified from Domen et al.173  Donor BM cells were 
magnetically enriched for Sca1+ cells on AutoMACS (Miltenyi Biotec).  The Sca1+ 
fraction was stained for Lin-/lowc-Kit+Sca1+Thy1low or Lin-/lowFlk2-c-Kit+Sca1+ and 
sorted twice in the presence of DAPI using the FACS Vantage DiVAII.  For the 
KTLS transplantation, 200 CD45.1 WT and 200 CD45.2 SHIP-/- KTLS cells were 
injected with 4x104 Sca1- CD45.1/45.2 WBM cells.  For the KFLS transplantation, 
100 CD45.1 WT and 100 CD45.2 SHIP-/- KFLS cells were injected with 4x105 
CD45.1/45.2 Sca1- cells.  CD45.1/45.2 recipients had been previously irradiated 
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with a split dose of 10Gy at 3-hour interval and given antibiotic water, as 
mentioned above. 
 
Assessment of Multi-Lineage Reconstitution 
 
For the first 4 months after transplantation the level of PB reconstitution 
was assessed, every 4 weeks, as a measure of engraftment of SHIP-/- and WT 
HSC.  PBMC were treated with Fc block, then stained with CD45.1-PE(A20), 
CD45.2-FITC (104), and APC-conjugated Lin markers; B220, CD3, or Mac1/Gr1 
(clones as previously mentioned).  The cells were then washed and resuspended 
in SM containing 7-AAD to exclude dead cells.  Data acquired on FACSCalibur 
with CellQuest and analyzed with FlowJo.  To assess the level of reconstitution 
of differentiated cells in the BM, spleen and PB 6 to 8 months after 
transplantation, we used the same antibody clones mentioned above except that 
Mac1 was conjugated to APCCy7 and Gr1 to APC.  Furthermore, DAPI was used 
for dead cell exclusion and data was acquired on a FACSAria using DiVaII 
software. To assess the level of KTLS reconstitution, BM cells were enriched for 
Sca1 on the AutoMACS (Miltenyi Biotec) using the Sca1-Biotin and anti-biotin 
magnetic beads (Miltenyi Biotec). Sca1+ cells were then stained for Lin-FITC, 
Sca1-biotin, c-Kit-APCCy7, Thy1-APC, CD45.1-PE and CD45.2-PerCPCy5.5.  
The Sca1-biotin was revealed using Streptavidin-PeCy7.  DAPI was used for 
dead cell exclusion.  Data was acquired on FACS Vantage with DiVaII software. 
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Annexin V Assay and TUNEL Assay 
 
BM cells were isolated stained with c-Kit-APCCy7, Thy1.2-APC, Lin-FITC, 
Sca1-Biotin and Flk2-PE on ice, biotin was revealed by streptavidin-PeCy7.  The 
cells were then incubated with Annexin V (BD Biosciences) according to the 
manufacturer’s protocol.  Analysis was done on a FACSAria using DAPI for dead 
cell exclusion.  TUNEL assay was performed using the In situ cell death 
detection Kit following manufacturer’s instruction (Roche Applied Science, 
Indianapolis, IN, USA).  First, BM cells were depleted of Lin+ cells using Lin-PE, 
anti-PE beads, and the autoMACS (Miltenyi Biotec), Lin- cells were then stained 
for KTLS and TUNEL. 
 
In Vivo Homing Assay 
 
Homing assays were optimized from previous protocols.147,175  BM cells 
from 6-8 week old SHIP-/- and WT mice were isolated from hind/fore limbs and 
from vertebral column.  BM cells were then RBC lysed, Fc blocked for 15 
minutes, then depleted of Lin+ cells using Lin-PE, followed by anti-PE beads, 
using autoMACS (Miltenyi Biotec).  Lin- cells were then stained for Lin-PE, Sca1-
FITC and DAPI and Sca1+Lin- cells were sorted on the FACS Aria.  After sorting, 
the cells were stained with 1μM of 9-H-(1,3-dichloro-9,9-dimethylacridin-2-one-7-
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yl) phosphate (DDAO-SE) (Molecular Probe/Invitrogen, Carlsbad, CA, USA) 
and/or 0.5 μM carboxyfluoroscein succinimidyl ester (CFSE) (Molecular 
Probe/Invitrogen) for 15 minutes at 37oC, washed and centrifuged at 300xg for 7 
minutes at 4oC.  Cells were then resuspended in PBS with 1mM HEPES and an 
equal number of live Sca1+Lin- SHIP-/- and WT cells (2x105 cells of each 
genotype) were then injected into irradiated recipient mice (1000 rads 3 hours 
prior to transplantation).  For some experiments, both CFSE stained SHIP-/- and 
WT Sca1+Lin- cells were injected in different recipients.  In others, CFSE stained 
SHIP-/- and DDAO stained WT Sca1+Lin- were injected in the same recipients.  
Twelve to 14 hours after injection, BM cells and splenocytes were isolated from 
recipients and directly analyzed on a FACS Aria in the presence of DAPI.  Five 
million events were collected for each recipient. 
 
Measurement Cytokines and Growth Factors Levels in Mice Sera 
 
Blood was obtained by sub-mandibular bleed, collected in a regular 
Eppendorf tube and left at RT for 4 hours to allow coagulation.  The blood was 
then stored at 4oC overnight.  The following day, blood clots were removed using 
a wooden stick and the remaining blood was centrifuged at 4000 RPM for 10 
minutes at 4oC. The sera was then isolated by taking the supernatant and sent 
for analysis at a custom based service at Charles Rivers Laboratories Inc., where 
ELISA for multiple cytokines and growth factors was performed. 
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Section II: Influence of SHIP on Megakaryocytes and Megakaryocyte Progenitors 
 
Introduction 
Megakaryocytes 
 
Platelets are responsible for repair of vascular damages, wound repair, 
innate immune response, and metastatic tumor cell biology.191  In human, 1 x 
1011 platelets are produced each day in order to maintain proper balance, and 
during time of crisis, this number can increase up to 10 fold.192  Mature 
megakaryocytes (MK) that are responsible for the production of platelets arise 
from the differentiation and maturation of megakaryocyte progenitors (MKP).  In 
turn, MKP are derived from early myeloid progenitors, which also give rise to 
granulocytes/monocytes and erythrocytes (Figure 4).  The different stages of 
MKP differentiation, from MKP proliferation to platelet shedding, and the diverse 
cytokines influencing that process, are depicted in Figure 19.  From early 
progenitor proliferation, MKP maturation to platelet shedding by MK, the 
megakaryocyte lineage has a unique way to control its homeostasis, mainly 
through chemokines, growth factors, and cytokines.193-196; 197-210  As it is shown 
on Figure 19, some cytokines are more important for the early development or 
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proliferation of MKP, such as IL-3 and c-KitL, while others, including IL-6 and 
mostly TPO impact MK maturation and platelet release.  One major component 
of MK maturation is the process of endomitosis, which generates MK that have 
an average DNA content of 32N, and exhibit an increase in cell size, mRNA 
content, and protein production.211,212  After fragmentation of polyploid MK, 
approximately 3000 platelets are generated,213 all of which are small cells that 
lack a nucleus, but have a highly organized cytoskeleton, the major necessary 
components to control thrombosis; unique receptors and specialized secretory 
granules.214,215  The level of platelet in an organism must be tightly regulated to 
prevent blood clot due to unwarranted production of platelet or excessive 
bleeding caused by a decrease in platelets levels. 
 
 
 
 
70 
  
 
Figure 19.  Megakaryocytopoiesis and cytokines that influence the process.  The 
different steps of megakaryocytopoiesis are influenced by many cytokines in vitro and in 
vivo.216,217  While the in vivo deletion of IL-3, IL-6, IL-11 and LIF does not affect 
megakaryocyte development, knockout mouse model for SF, TPO, and its receptor Mpl 
exhibit a megakaryocyte development defect.  Interestingly, treatment of Tpo-/- and Mpl-/- 
mice with FGF-4 and SDF-1 induced platelet production to levels comparable to WT.200 
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The Involvement of SHIP in MK Signaling Pathway 
 
Early on many cytokines, including IL-3, IL-6, IL-11, LIF, c-KitL, Epo and 
G-CSF have been shown to impact megakaryocytopoiesis and 
thrombopoiesis.193-197  It was shown that they can influence megakaryocyte 
progenitor (MKP) proliferation and differentiation, in vitro, in a synergistic manner, 
none of them being sufficient to promote megakaryocytopoiesis alone.  However, 
it was always believed that megakaryocytopoiesis was controlled by a major 
growth factor that still had to be discovered.  Even though the cytokine TPO was 
not physically isolated before 1994, the word thrombopoietin was first used in 
1958 to describe a factor that would stimulate platelet production in mice and 
human.201-203 
 
 
In 1994, several groups identified and cloned the humoral factor primarily 
responsible for MKP and MK proliferation and maturation.204,205,209  These groups 
identified TPO, as a molecule that can bind to c-mpl,204,205,209 a cellular proto-
oncogene from a human erythroid leukemia cell line with strong homology to v-
mpl, murine myeloproliferative leukemia virus oncogene.218,219  Administration of 
TPO leads to a strong enhancement of MKP/MK proliferation, maturation and 
polyploidization,205,207,210 as well as a dramatic increase in platelet numbers.208  
TPO is constitutively produced by kidney and liver, and the control of its 
production appears not to be at the mRNA levels but to depend on platelet 
numbers.220  One of the major mechanism by which TPO regulates 
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megakaryocytopoiesis appears to be based on the level of free (unbound) TPO 
available in the blood,221 such that free TPO levels in the blood are inversely 
proportional to the amount of platelets.222  If platelets levels are high, most of the 
TPO is bound to platelets, leading to a decrease in the megakaryocytopoiesis 
process.  As levels of free TPO increase in the blood after injury or platelet insult, 
the megakaryocytopoiesis process is induced in order to replace the lost 
platelets. 
 
 
TPO was initially thought to be a lineage specific cytokine that induces 
megakaryocytopoiesis in vivo and in vitro.  However, TPO is now known to have 
an important role in the biology of several other hematopoietic cell types such as 
erythrocytes,223-225 granulocytes/macrophage,223-225 neutrophils-colony forming 
cells (CFC),225 and hematopoietic stem/progenitor cells.184,225-227  Although TPO 
is the primary regulator for megakaryocytopoiesis, it has been shown that c-mpl 
and TPO deficient mice still have a reduced level of functional platelets, their 
numbers being 85% that of WT mice.206,228  This suggests that other factors can 
impact megakaryocytopoiesis independently of TPO.  It was demonstrated by 
several groups that SDF-1 can impact thrombopoiesis and in combination with 
other chemokines can compensate for TPO deficiency.198,199,205,229,230  In fact, 
SDF-1 and FGF-4 have recently been shown to have the capacity to palliate TPO 
deficiency.200  Simultaneous administration of SDF-1 and FGF-4 to Tpo-/- and c-
mpl-/- mice, through an adenoviral system, led to a recovery of platelet numbers 
similar to the one observed in WT mice.200  It appears that these chemokines are 
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important for the interaction of MK with sinusoidal BM endothelial cells, 
promoting their maturation and platelet shedding.198,200  It was also shown that 
SDF-1 induces transendothelial MK migration and platelet production in vitro199 
and in vivo.230  Moreover, SDF-1 appears to enhance human thrombopoiesis in 
xenotransplanted NOD/SCID mice.231  Interestingly, it was shown that SHIP 
might impact signaling pathways downstream of SDF-1.27,152  In that study, the 
authors observed that CXCR4 engagement by its ligand SDF-1, led to 
phosphorylation and recruitment of Shp-2.  In this cell context, Shp-2 was found 
in a protein complex including the proteins SHIP, cbl, and fyn.27  Furthermore, 
SHIP-deficient myeloid progenitors exhibit enhanced chemotaxis towards SDF-
1.152 
 
When TPO binds to c-mpl, it induces phosphorylation and/or activation of 
an array of signaling molecules including proteins in the JAK/STAT pathway, 
STAT3, STAT5, Shc, Lyn, SHIP and PI3K.191,232-236  In that cell context, PI3K 
converts PI(,4,5)P2 to PI(3,4,5)P3, the latter can then recruit PH domain containing 
proteins, leading to Akt activation, increased cell survival and proliferation of 
MK.235  Interestingly, TPO activation of PI3K in mature platelets result in 
enhanced α-granule secretion and thrombin induced aggregation activation.237   
 
SHIP has been shown to oppose PI3K signaling by removing the 5’ 
phosphate of PI(3,4,5)P3,2,3,5 and to be phosphorylated following c-mpl 
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engagement by TPO in mature MK and c-mpl transfected BA/F3 cells.235  
Therefore, SHIP could block this key signaling pathway downstream of the c-mpl 
receptor 152,238  On the other hand, engagement of c-mpl by TPO leads to Shc 
phosphorylation and association with Grb2/SOS, resulting in the promotion of 
Ras activation of the MAPK pathways.24,239,240  Knowing that SHIP can compete 
with Grb2 for binding to Shc, SHIP could negatively control the MAPK pathway 
activation.1  Furthermore, other cytokines that have been shown to play a role in 
megakaryocytopoiesis are known to stimulate or to depend on SHIP for the 
dampening of their signaling pathways, including IL-3, c-KitL, and G-
CSF.3,13,22,216,241,242  Interestingly, Lyn-/- mice exhibit an increase in 
megakaryocytopoiesis.243,244  Lyn kinase is a negative regulator of cell signaling 
pathways downstream of receptors for different cytokines including M-CSF and 
TPO.45,236  Lyn is known to phosphorylate and recruit SHIP to the membrane 
after cytokine stimulation of the cells.  Since SHIP is important for the negative 
control of several signaling pathways downstream of cytokines implicated in 
megakaryocytopoiesis, we hypothesize that SHIP-deficient mice might show an 
increase in megakaryocytopoiesis and thrombopoiesis. 
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Aims: 
 
1) Assess the level of MK and MKP in SHIP-/- mice hematopoietic organs by flow 
cytometry as compare to WT mice. 
2) Attempt to identify the factors responsible for the perturbation of the MK 
compartment. 
 
Results 
 
MKP are Increased in the BM and Spleen of SHIP-Deficient Mice 
 
We analyzed BM, spleen and PB from SHIP-/-, SHIPΔIP/ΔIP, and their 
respective WT littermates to determine the size of the MKP compartment in vivo 
by flow cytometry (Figure 20A), using an immunophenotype defined by Hodohara 
and colleagues,245 Lin-c-Kit+CD41+, which contains the majority of CFU-Mk 
activity.  We observed an expansion of the MKP compartment in the BM of SHIP-
/- and SHIPΔIP/ΔIP mice as compared to their WT littermates (Figure 20BI).  In fact, 
SHIP-/- and SHIPΔIP/ΔIP BM showed a mean 18.1-fold and 50-fold increase, 
respectively, in the absolute number of MKP relative to WT controls (Figure 
20BI).  However, the numbers of MK, as defined by the immunophenotype Lin-c-
Kit-CD41+, were decreased by a mean 2-fold in SHIPP-/- and SHIPΔIP/ΔIP BM as 
compared to WT control (Figure 20CI). 
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Figure 20.  Increased number of MKP in SHIP-deficient BM.  (A) Flow cytometry analysis 
of BM, spleen, and PB from SHIP-/- (-/-) and SHIPΔIP/ΔIP (ΔIP/ΔIP) and WT littermates.  
Representative flow cytometry plot of c-Kit vs. CD41 after gating on live cells and Lin- 
cells.  MKP are in the upper right quadrant and MK in the lower right quadrant.  
Percentages for each population are indicated on the plot.  (B) Bar graph showing the 
absolute numbers of MKP (Lin-c-Kit+CD41+) cells in (I) BM (sum of 2 femurs + 2 tibias), 
(II) whole spleen and (III) per μl of PB.  (C) Bar graph showing the absolute numbers of 
MK (Lin-c-Kit+) cells in (I) BM (sum of 2 femurs + 2 tibias), (II) whole spleen and (III) per 
μl of PB.  Bar graphs showing the different SHIP-deficient models (black) and their 
respective WT littermates (gray).  Data acquired using FACS Calibur, CellQuest 
software and analysis done with FlowJo.  Significance was established using the 
unpaired student t test (Prism 4): ***p<0.0001, +++p<0.0005, ++p<0.005, and +p<0.05.  
(mean ± SEM, n≥3).  Collaboration with N. Parquet and LE Perez MD. 
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The observation of splenocytes for the presence of MKP and MK by flow 
cytometry (Figure 20A, Bii, Cii) revealed that SHIP-/- and SHIPΔIP/ΔIP spleens 
exhibited higher percentages of MKP and MK as compared to WT littermates 
(data not shown).  The absolute number of splenic MKP was increased by at 
least 30-fold in both, SHIP-/- and SHIPΔIP/ΔIP mice, as compared to their respective 
WT littermates (Figure 20BII).  Furthermore, the absolute number of splenic MK 
was increased by a mean 10.9-fold in SHIP-/- spleen as compared to WT 
littermates (Figure 20CII).  SHIPΔIP/ΔIP mice exhibited an even more dramatic 
increase in the absolute number of splenic MK as compared to WT control 
(Figure 20Cii).  Analysis of PB for the presence of MK and MKP by flow 
cytometry revealed that it contains very few MKP, with an average of 3 to 5 
MKP/μl.  Using this method, we observed that the number of MKP was not 
significantly increased in SHIP-/- mice when compared to WT (Figure 20BIII).  
However, MKP numbers were slightly, but significantly higher, in SHIPΔIP/ΔIP PB 
as compared to WT littermates (Figure 20BIII).  Furthermore, in the PB of SHIP-/- 
mice there was a mean 7.7-fold increase in the absolute number of MK and the 
same trend was observed for SHIPΔIP/ΔIP mice (Figure 20CIII). 
 
We then combined the number of MKP and MK present in the BM and 
spleen in SHIP-deficient mice as compared to WT controls (Figure 21).  In both, 
the SHIP-/- and SHIPΔIP/ΔIP mice, the total MKP numbers were increased by a 
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mean 3.5-fold as compared to their respective WT littermates (Figure 21A).  
Despite an increase in total MKP numbers in SHIP-deficient mice, we observed 
that these mice have a comparable total number of MK as compared to WT 
littermates (Figure 21B).  Thus, the decrease in MK numbers observed in SHIP-
deficient BM (Figure 20Bi) is compensated for by the increase in splenic MK 
numbers (Figure 20Ci).  This results in SHIP-deficient mice containing a 
comparable number of total MK as compared to WT littermates. 
 
Figure 21.  Total MKP but not total MK numbers are increased in SHIP-deficient mice 
are compared to WT.  The total number of MKP and MK was calculated by adding the 
absolute number MKP or MK in the spleen and 
whole BM of one mouse.  To calculate the 
number of MKP and MK in the whole BM of a 
mouse, multiply the number of MKP or MK in one 
femur by a 16.6.156  (A)  Total absolute number of 
MKP in the spleen and whole BM of SHIP-
deficient mice and their WT littermates.  (B)  Total 
absolute number of MK in the spleen and whole 
BM of SHIP-deficient mice and their WT 
littermates.  Data acquired using FACS Calibur, 
CellQuest software and analysis done with 
FlowJo.  Significance was established using the unpaired student t test (Prism 4): 
+++p<0.0005 and ++p<0.005.  (mean ± SEM, n≥3). 
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MKP and MK are Increased in BM and Spleen of SHIP-Ablated Mice 
 
To observe if inhibition of SHIP during adulthood could also result in an 
increase in MKP production, we used the MxCre model.  This model is described 
in the previous section on SHIP and HSC.  Briefly, the treatment of MxCRE+fl/fl 
mice with polyIC will lead to Cre recombinase expression through Type 
interferon-inducible Mx1 promoter, and deletion of the gene section between two 
loxP sites.  In this case, the promoter and the first exon of the SHIP gene will be 
deleted resulting in the ablation of SHIP expression.  As control, MxCre-/SHIPfl/fl 
are treated with polyIC in the same manner than the MxCRE+fl/fl mice.  Twenty-
one days after the last polyIC treatment, mice were euthanatized and the level of 
MKP was evaluated by flow cytometry (Figure 22Ai).  As observed in Figure 19Bi 
we see an increase in the percentage of MKP in the BM and spleen of SHIP-
ablated mice as compared to MxCre- mice.  Furthermore, we observe that SHIP-
ablated BM contains approximately 4 times more MKP than their MxCre- 
counterpart (Figure 22Bii).  As for the germline SHIP-/-, we also observe an 
increase in the percentage of MK present in the spleen (Figure 22Biii).  This 
result suggests that mice that undergo normal development can also exhibit 
increased MKP numbers once SHIP is deleted during adulthood.  This has some 
therapeutic implication, where SHIP inhibition could be used to increase in 
megakaryocytopoiesis in adult patients. 
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Figure 22.  Significant increase in the percentage of MKP cells in SHIP-ablated BM and 
spleen.  MxCre+ and MxCre- mice with floxed SHIP alleles were treated with polyIC 3 
times prior to being analyzed.  (A) Representative FACS plots showing detection of and 
MK and MKP in the BM and spleen of MxCre+ and MxCre- mice after treatment.  (B) (i) 
Percentage of MKP in BM (top), spleen (Spl) (bottom) and of SHIP-ablated (black) and 
WT (grey) mice. (ii) Absolute number of MKP cells in BM (per femur and tibia pair). (iii) 
Percentage of MK found in the spleen.  Data acquired on a FACS Calibur with CellQuest 
software (BD Biosciences, San Jose, CA), analyzed with FlowJo.  Significance was 
established using the unpaired student t test (Prism 4). +++p<0.0005, ++ p<0.005, and 
+p<0.05.  (mean ± SEM, n≥3). 
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Platelet Levels are Lower in SHIP-Deficient Mice as Compared to WT Mice 
 
One striking observation is that despite the profound expansion of the 
MKP in SHIP-/- and SHIPΔIP/ΔIP mice, these mice do not exhibit increased platelet 
levels relative to WT controls, when measured by hematolyzer (Table 2).  The 
analysis of SHIP-/- and SHIPΔIP/ΔIP PB revealed that these mice have a significant 
reduction in their platelet as compared to WT littermates (Table 2).  Furthermore, 
SHIP-/- as well as SHIPΔIP/ΔIP mice PB have a significantly lower percentage of 
hematocrit.  SHIP heterozygous mice platelet and hematocrit levels were not 
significantly different than the WT levels.  The hematocrit percentages and 
platelet counts observed in PB isolated from SHIP heterozygous mice were not 
significantly different than the one observed for the WT PB (Table 2) all p values 
being above 0.5.  Except for SHIP+/- PB hematocrit percentage (p=0.072), all 
heterozygous values shown in Table 2 were significantly difference than the 
values observed for their respective SHIP-deficient PB. 
Table 2.  Platelet and Hematocrit counts in SHIP-deficient mice. 
Mice genotype Platelet levels (#x103/μl) Hematocrit (%) 
   
SHIP-/- 672.8 ± 43.4++ 42.5 ± 1.4+
SHIP+/- 848.9 ± 35.7 45.2 ± 0.5 
SHIP+/+ (C57Bl6) 803.7 ± 31.5 46.6 ± 0.5 
   
SHIPΔIP/ΔIP 455.4 ± 81.1++ 43.1 ± 1.4++
SHIP+/ΔIP 652.3 ± 28.0 46.8 ± 0.5 
SHIP+/+(129SvJ) 647.9 ± 28.0 47.0 ± 0.6 
+ p < 0.05 compared to their respective WT littermates 
++ p < 0.05 compared to their respective WT and SHIP heterozygous littermates 
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SHIP-Deficient MK are Morphologically Different than WT MK 
 
BM histopathology revealed that MK in SHIP-/- BM have a hypolobulated 
micromegakaryocytic morphology when compared to WT BM, which contains 
mature hyperlobulated MK (Figure 23A).  The increase in MK numbers found by 
flow cytometry in the SHIP-deficient spleens was corroborated by morphology, 
where the spleens of SHIP-deficient mice have a qualitative increase in the 
number of MK (Figure 23B).  These observations suggest a shift in the site of 
megakaryocytopoiesis from the BM to the spleen.  This is in agreement with 
other findings suggesting that the spleen of SHIP-deficient mice becomes the site 
of intense extramedullar hematopoiesis.95,156,246 
 
Figure 23.  Hematoxylin-eosin 
staining of SHIP-deficient WT 
BM and spleen.  (A) 
Hematoxylin-eosin staining of 
SHIP-/- and WT BM section, 
photographed at 63x. (B) 
Hematoxylin-eosin staining of 
SHIPΔIP/ΔIP and WT spleen 
section, the images were 
photographed at 40x (spleen).  
Cells were visualized on a 
Leica DM LB microscope.  Pictures were taken using a RTcolor Spot camera (Diagnostic 
Instrument Inc) with Spot Advance v3.0 software.  Collaboration with N. Parquet and 
L.E. Perez MD. 
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Comparable Ploidy Distribution in SHIP-/- MK as Compared to WT 
 
The hypolobulated micromegakaryocytic morphology of SHIP-/- BM MK 
cells observed by histology suggested that these cells did not mature properly.  
Therefore, we evaluated the ploidy distribution in BM and splenic SHIP-/- MK, as 
endomitosis is an obligatory step towards MK maturation.  However, these 
results revealed that SHIP-/- BM and splenic MK cells have a similar ploidy 
distribution than WT MK (Figure 24).  Thus, SHIP-/- Lin-CD41+ cells do exhibit a 
similar ploidy distribution, thus have a comparable ability to undergo 
endoreplication as compared to WT Lin-CD41+ cells (Figure 24A, B). 
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Figure 24.  SHIP-/- MK undergo endocytosis with the same efficiency as WT MK.  BM 
cells and splenocytes from SHIP P-/- and WT mice were enriched for CD41+ on 
AutoMACS, stained with Lin-panel and CD41-biotin/SA-APC, fixed/permeated and 
stained with PI in the presence of RNase.  (A) Representative gating strategy to obtain 
the final FACS plot used to calculate the DNA content of Lin-CD41+ cells.  (B) 
Representative FACS plot used to calculate the DNA content of BM and spleen Lin-
CD41+ cells for SHIP-/- and WT.  (Ci) Bar graph representing the percentage of BM Lin-
CD41+ cells in the different ploidy stage visible on the plot.  (Cii) Bar graph with 
emphasis on the higher ploidy distribution for BM Lin-CD41+ cells.  (Di) Bar graph 
representing the percentage of spleen Lin-CD41+ cells in the different ploidy stage visible 
on the plot.  (Dii) Bar graph focusing on the higher ploidy distribution for spleen Lin-
CD41+ cells  Data acquired using FACS LSR, DiVaII (BD Biosciences).  Statistical 
analysis was done using the unpaired student t test (Prism 4).  (mean ± SEM, n≥3). 
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TPO Levels are Increased in SHIP-/- Plasma as Compared to WT 
 
It has been proposed that SHIP might contribute in the control of pathways 
downstream of c-mpl, and the lack of SHIP could result in a higher response to 
TPO stimulation as compared to WT littermates.  However, an increase in sera 
TPO levels could also result in increased megakaryocytopoiesis.  Therefore, we 
assessed the level of TPO in SHIP-/- mice sera.  Consistent with the decreased 
platelet levels (Table 2) and the increased megakaryocytopoiesis (Figure 20) 
observed in SHIP-/- mice, we saw that SHIP-/- sera contained a significantly 
higher concentration of TPO as compared to WT mice.  ELISA performed on 
SHIP-/- and WT sera revealed that SHIP-/- sera had a concentration of 12.8 ± 0.2 
ng/ml of TPO while WT had 11.67 ± 0.2 ng/ml (Figure 25A).  Although this is only 
a difference of 1.2 ng/ml, it is statistically significant according to an unpaired 
student t test (p<0.005) (Figure 25A).  Furthermore, IL-6, a cytokine that has 
been shown to impact early megakaryocytopoiesis216 and TPO production during 
inflammation,247 was increased in SHIP-/- mice sera as compared to WT (Figure 
25B), this was also observed in another SHIP knock-out model at the mRNA 
level.  However, not all factors shown to impact megakaryocytopoiesis were 
increased in SHIP-/- mice as shown in Figure 25C, LIF levels in SHIP-/- mice were 
not significantly different from WT mice.  The increase in IL-6 and TPO observed 
in SHIP-/- sera could contribute to the increase in megakaryocytopoiesis 
observed in these mice. 
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Figure 25.  TPO levels are significantly increased in SHIP-/- sera as compared to WT 
littermates.  Mice were bled by sub-mandibular bleeding and the blood was collected in 
regular Eppendorf tube to allow coagulation.  The sera was then collected and sent for 
analysis by ELISA (Charles River Laboratories Inc.).  (A)  Levels of TPO in SHIP-/- 
(square) and WT (triangle) sera. (B) Levels of IL-6 in SHIP-/- (square) and WT (triangle) 
sera. (C) Levels of LIF in SHIP-/- (square) and WT (triangle) sera.  Significance was 
established using the unpaired student t test (Prism 4).  ++ p<0.005  (mean ± SEM, 
n≥3). Collaboration with D. Woods and WG Kerr Ph.D. 
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Discussion 
 
The ablation of SHIP results in an augmentation of MKP production.  
However, we observe that the total number of MK in SHIP-deficient mice is 
comparable to the one observed in WT.  The decrease number of MK in the BM 
of SHIP-deficient mice appears to be compensated for by a dramatic increase in 
splenic MK.  Therefore, there are some indications that in SHIP-deficient mice 
the mature MK leave the BM prematurely to be found in the periphery, in the 
spleen and PB.  The shift in MK localization from the BM to the periphery might 
result from an increased responsiveness to SDF-1, which can cause trans-
endothelial migration of MK from the BM to the circulation.198-200  Thus, SHIP may 
participate in the control of pathways downstream of CXCR4 mediating MK 
migration, as it does in myeloid progenitors.152  Alternatively, the increase in 
peripheral MK might result from extramedullar hematopoiesis as it was shown 
that SHIP-deficient spleen contain elevated levels of HSC156,246 and 
hematopoietic progenitors (Figure 21B).95 
 
We observe that MK cells in the BM of SHIP-deficient mice are 
hypolobulated and less mature than the one found in WT BM by looking at 
morphology (Figure 23).  This would suggest that SHIP-deficient BM MK cells do 
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not mature properly.  However, we observed that BM, like splenic, SHIP-/- MK 
exhibited a comparable ploidy distribution as the one seen for WT MK cells.  This 
result suggests that the SHIP-deficient BM MK mature as well as WT BM MK.  
Alternatively, SHIP-/- MK might exit the BM prematurely, before the shedding of 
platelets, as they might be more responsive to SDF-1 induced migration 
signaling. 
 
 
Platelet levels limit megakaryocytopoiesis by sequestering TPO.216  These 
platelets have c-mpl receptors on their surface that can bind TPO molecules.248  
Therefore, it has been suggested that the level of free-TPO in circulation is 
inversely proportional to platelet levels.249  Thus, a decrease in platelet levels 
would cause an increase in free-TPO and stimulate megakaryocytopoiesis in 
order to replenish the platelet stock.  In SHIP-deficient mice, we observed a 
significant decrease in platelet levels and, consequently, a significant increase in 
TPO levels as compared to WT controls.  The increase in free-TPO might 
stimulate the proliferation and/or survival of MKP in SHIP-deficient mice, leading 
to an expansion of the megakaryocytic compartment.  Furthermore, SHIP-
deficient MKP could be hyper-responsive to the free-TPO available since it was 
shown previously that SHIP is phosphorylated after c-mpl engagement with TPO 
in primary MK and c-mpl transfected Ba/F3 cells.235.  Administration of TPO to 
patients or test animals causes the increase in platelet levels only a few days, 3 
to 5, after treatment.250  This suggests that TPO does not regulate directly 
release of platelet but mainly the proliferation and maturation of MKP and MK 
89 
  
respectively.  Thus, the increase in MKP numbers but not in platelet levels in 
SHIP-/- mice might further suggest that megakaryocytopoiesis and platelet 
shedding are regulated by different mechanisms. 
 
Furthermore, it is worth noting that SHIP has been shown to be present in 
human platelets and to be responsible for the production of PI(3,4)P2 during 
aggregation dependent activation of platelets.  PI(3,4)P2 in human platelets was 
shown to mediate actin assembly for filopodial growth,251 and sustained exposure 
of integrin GpIIB-IIa leading to irreversible aggregation.251-253  This process is 
probably hindered in SHIP-deficient platelet since it is responsible for removing 
the 5’ phosphate of PI(3,4,5)P3, to create PI(3,4)P2.  Thus, SHIP-deficient platelet 
might have compromised function, affecting their activation status and causing 
premature elimination from the circulation. 
 
 
As mentioned earlier, we observe a significant decrease in the mean 
platelet numbers in SHIP-/- mice as compared to WT mice.  This could in part 
explain the increase in TPO levels observed in these mice.  However, researches 
have shown that inflammation can contribute to increasing TPO production.247  
Actually, cytokines produced by monocytes, including macrophages, can induce 
a chain reaction, involving an increase in IL-6 levels, promoting increased 
production of TPO by the liver.191,247  SHIP-/- mice have increased number of 
macrophages in their BM, spleen and periphery,95 and we observe that these 
mice exhibit significantly higher IL-6 levels (Figure 25B).  In fact, we observed 
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that SHIP-/- mice have 49 pg/ml of IL-6 in their sera as compared to 1 pg/ml for 
WT (Figure 25B).  This increase IL-6 sera concentration could induce TPO 
production by the liver 
 
Furthermore, we observe that both SHIP-deficient models exhibit a 
decrease in hematocrits as compared to their respective WT (Table 2).  
Helgason et al reported that F2 SHIP-/- mice (129 mice backcrossed twice to 
C57Bl6 mice) have no difference in hematocrit levels compared to WT.  
However, a more recent publication reveals that F6-7 SHIP-/- mice exhibit a 
significant decrease in hematocrit levels as compared to WT.254  In this later 
paper, it was mentioned that the increased severity of the erythroid defect might 
result from backcrossing onto C57Bl6 strain.  However, since the SHIP ΔIP/ΔIP 
mice are on a mixed background, this explanation seems unlikely.  Looking back 
at the data published in 1998, there was already a great difference in the 
percentage of hematocrits between WT and SHIP-deficient mice with 50.7±1.0% 
for WT versus 42.4±5.7 for SHIP-deficient mice.  However the standard error 
mean was large for SHIP-deficient mice, probably caused by a small sample 
population.95  In the second study, they seem to have used a larger sample 
group,254 which could have helped reduce the standard error mean, and show a 
significant difference between the two sample groups. 
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Our results suggest that SHIP negatively controls pathways promoting 
early megakaryocytopoiesis.  However, the fact that we observe a similar level of 
MK in SHIP-/- and WT mice suggests that different pathways control MKP 
proliferation, MK maturation and platelet shedding.  On the other hand, SHIP-
deficient MK could leave the BM prematurely due to increased responsiveness to 
SDF-1, which could hamper MK maturation and the platelet shedding process. 
 
These findings suggest that SHIP could be targeted in vivo to increase the 
pool of MKP, and subsequently enable this compartment to replenish platelets 
more rapidly following myeloablative chemotherapy and radiation treatment.  
However, this assumes that SHIP deficiency does not adversely impact MK 
maturation, platelet shedding from MK or platelet function. 
 
Materials and Methods 
Mice Strains 
 
SHIP-/- mice (F9 or F10 X C57BL6/J) produced in our laboratory have a 
deletion of the SHIP promoter and first exon.43  A second SHIP-deficient mouse 
model was also analyzed, SHIPΔIP/ΔIP (129SvJ),97 in which the inositol 
phosphatase domain is deleted was kindly provided by Dr. Jeffrey Ravetch, 
Rockefeller University, NY, USA.  All studies described herein were conducted 
on six to eight week-old adult mice.  For the inducible model, SHIP fl/fl mice were 
 
92 
  
backcrossed to MxCre germline.  The resulting MxCre+fl/fl and MxCre-fl/fl mice 
were treated 3 times with 625 μg polyIC in the course of 7 days.  Mice were 
analyzed at least 21 days after the last injection.  Experiments were performed in 
compliance with institutional guidelines of the University of South Florida. 
 
Cell Isolation 
 
Isolation of BM cells and splenocytes was as described previously.246  
Following red blood cell (RBC) lysis, the cells were resuspended in staining 
media..246   PB was obtained from the retro-orbital sinus, sub-mandibular bleed 
or heart puncture.  For MKP analysis of PB, RBC were lysed twice in 1x RBC 
lysis buffer (eBioscience).  Cells were then resuspended for antibody staining. 
 
Flow Cytometry Analysis and Antibodies 
 
Staining of MKP and MK was performed as per Hodohara et al245  All 
antibodies were from BD Biosciences except when mentioned otherwise.  The 
cells were treated with anti-CD16/CD32 (2.4G2) to block Fc receptors and then 
stained with a Lin panel-PE, CD41-FITC(MWReg30), and c-Kit-APC(2B8).  The 
Lin- panel was CD3ε(17A2), CD4(GK1.5), CD8α(53-6.7), B220(RA3-6B2), Gr-
1(RB6-8C5), Mac-1 (M1/70) (Caltag, Burlingame, CA) and Ter119(TER-119).  
Dead cells were excluded using 7-AAD (BD Biociences).  Data was acquired on 
 
93 
  
a FACS Calibur using the FACS Quest software and analysis was done using 
FlowJo 4.5. 
 
Platelet Analysis 
 
Blood was collected by heart puncture or sub-mandibular bleed and 
platelets were quantified using the CellDyn 3700 hematology analyzer (Abbott 
Diagnostic, Dallas, Texas USA). 
 
Histopathology 
 
Bone and spleen were fixed in 10% buffered paraformaldehyde.  Bone 
were first decalcified using Routine Acid Decalcification (RDO; Apex engineering 
Products, Plainfield, IL, USA), followed by sectioning.  The spleen and bone 
sections were then stained with hematoxylin-eosin after being deparaffinized with 
xylene.  Briefly, slides were stained using the modified Meyer’s hematoxylin and 
eosin phloxine B solution (Fisher Scientific, Suwanee, GA, USA) according to a 
modified Armed Forces Institute of Pathology (AFIP) protocol.  Cells were 
visualized on a Leica DM LB microscope.  Pictures were taken using a RTcolor 
Spot camera (Diagnostic Instrument Inc) with Spot Advance v3.0 software. 
Ploidy assay 
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BM cells were isolated from hind/fore limb and vertebral column.  Briefly, 
cells were incubated with CD41-biotin antibody (Serotec, Raleigh, NC, USA) on 
ice and then with anti-biotin beads (Miltenyi Biotec) at 4oC.  CD41+ cells were 
then selected using the autoMACS (Miltenyi Biotec).  Collected CD41+ cells were 
stained with Lin panel-FITC as mentioned above and with streptavidin-APC (BD 
Biosciences).  The cells were fixed in 1% formaldehyde (Sigma-Aldrich) for 15 
minutes on ice and then incubated overnight in a 70% ethanol solution at -20oC.  
The day after, the cells were washed carefully of any residual ethanol with PBS 
and incubated for at least 3 hours in a propidium iodine (PI) solution composed of 
50 μg/ml PI, 0.1% Triton X-100, 2.5U/ml RNase in PBS without Ca or MG (all 
from Sigma-Aldrich except for the PBS which was from Gibco BRL/Invitrogen). 
 
Measurement of Cytokines and Growth Factors Levels in the Sera of 
Experimental Mice 
 
Blood was obtained by sub-mandibular bleed, collected in a regular 
Eppendorf tube and left at RT for 4 hours to allow coagulation.  The blood was 
then stored at 4oC overnight.  The following day, blood clots were removed using 
a wooden stick and the remaining blood was centrifuged at 4000 RPM for 10 
minutes at 4oC. The sera was then isolated by taking the supernatant and sent 
for analysis at a custom based service at Charles Rivers Laboratories Inc., where 
ELISA for multiple cytokines and growth factors was performed. 
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Section III: Natural Killer Cells and SHIP 
 
Introduction to Natural Killer Cells 
 
NK cells were first defined as a cell fraction residing in the spleen, with the 
ability to spontaneously kill tumor cells without prior immunization.255-257  
However, it is now known that NK cells are found in the BM, liver and PB.  NK 
cells are derived from the same progenitor cell as T-lymphocytes, either the 
common lymphocyte progenitor in BM or the NK-T cell precursor in fetal liver.258  
Although common in origin key difference do exist between the two cell types.  
One primordial distinction is that NK cells do not undergo the maturation process 
that T-cells go through in the thymus and are unable to accomplish gene 
rearrangement for the production of antigen specific receptors.259  Furthermore, 
NK cells are part of innate immunity, and the first line of defense of an organism 
against viral infection and tumorigenic transformation of host cells.255-257  These 
cells can kill target cells either by direct cell-mediated cytotoxicity or by secretion 
of soluble factors.  To this effect they can produce diverse cytokines, such as IL-
5, IL-10, IL-13 and GM-CSF.260  However, NK cells secrete predominantly 
interferon-γ (IFN-γ), which helps control tumor cell proliferation and kill virally 
infected cells.261,262  In fact, it was shown that NK cells store IFN-γ transcripts,263 
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which can be rapidly released upon stimulation.  They also express molecules 
member of the Tumor necrosis factor (TNF) family such as, TNFα, Fas ligand 
(FasL) and TNF related apoptosis inducing ligand (TRAIL), which bind to death 
domain-containing receptors on target cells causing their apoptosis.264,265  Most 
importantly, NK cells contain granules storing perforin and granzyme,266-268 all of 
which can be secreted shortly after stimulation.  For example, perforin dependent 
cytotoxicity can be mediated within 20 minutes after activation of NK cells.269  
Thus, as soon as these cells encounter a potential target, they are ready for 
action.  It is therefore suited that NK cells be tightly regulated by an array of 
receptors that trigger activation and inhibitory response depending on the target 
cell and cytokines present.270  This fine balance between inhibition and activation 
prevents inadvertent killing of normal healthy host cells. 
 
Activation of NK cells by engagement of activating receptors leads to the 
stimulation of kinases that triggers cytolysis of target cell.  The whole process 
remains to be further elucidated, but to date we know that several molecule 
become phosphorylated or recruited during NK cells activation, including Syk,271 
SLP-76,272 ZAP-70,273 Linker for activation of T cell (LAT),274 Shc,275 PI3K,276,277 
PLCγ1 and 2.278-280  Interestingly, it was observed that NK cells ablated for Syk 
and ZAP-70 can develop normally and lyse tumor cells in vitro and in vivo.281  
Thus, these molecules are used for activation of NK cells but are not essential.  
On the other hand, simultaneous inhibition of PI3K and Src kinases prevented 
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the cytolytic activity of these mutant NK cells and strongly reduced that of WT NK 
cells, suggesting that distinct and redundant signaling pathways act in a 
synergistic manner to trigger cytotoxicity.281  To this end, PI3K is known to 
mediate the production of PI(3,4,5)P3, which lead to calcium increase and 
activation of PLCγ molecules.  PLCγ-2 ablated NK cells were shown to be greatly 
reduced in their ability to lyse target cells and secrete IFN-γ in response to 
stimulation of signaling pathways mediated by DNAX adapter protein-10 (DAP-
10), which contains an ITAM motif.279  Furthermore, PLCγ-2 ablated NK cells 
have a disrupted receptor repertoire, particularly for Ly49 receptors.279 
 
NK Cell Receptors 
 
As mentioned above NK cell cytotoxic activity is regulated by a fine 
balance between activating and inhibitory receptors.  The inhibitory receptors 
expressed by NK cells are many and differ in structure and ligand specificity.  
These receptors are encoded in a defined region on chromosome 6 that was 
named “the NK cell gene complex”.282  This chromosomal region encodes for 
series of receptor molecules that can form disulfide–bound homodimers, 
characterized by being type II integral membrane proteins with C-type lectin 
domains.  The NK cell gene complex encode for the activation receptor such as 
CD69283 and for members of the Nkrp1 (NKR-P1A, B, C) multigene family.282,284  
Nkrp1-C, also called NK1.1, and part the of the Nkrp1 family285 is expressed on 
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NK cell and a subset of T cells, and even though its ligand is unknown it is 
believed that NK1.1 is an activation molecule since antibody cross-linking leads 
to activation of NK cells and lysis of target cells.286  Most importantly for this 
work, the NK cell gene complex encodes for members of the Ly49 receptor 
family, which is composed of at least 23 members (Ly49A through W) (Table 
3).287  The ligands for 14 of these receptors are known so far (Table 3).287   
Table 3.  Functions and ligands of Ly49 NK cell receptors 
Receptor Function Cellular Viral ligand 
name  Ligands  
Ly49A Inhibitory Db, Dd, Dp, Dk  
Ly49B Inhibitory ?  
Ly49C Inhibitory Kb, Kd, Kk, Dd, Db  
Ly49D Activating Dd  
Ly49E Inhibitory ?  
Ly49F Inhibitory Dd  
Ly49G Inhibitory Dd, Ld  
Ly49H Activating Db MCMV-m157 
Ly49I Inhibitory Kd MCMV-m158 
Ly49J Inhibitory Kb  
Ly49K* Activating ?  
Ly49L Activating Kk  
Ly49M Activating ?  
Ly49N* Activating ?  
Ly49O Inhibitory Db, Dd, Dk, Ld  
Ly49P Activating Dd  
Ly49Q Inhibitory ?  
Ly49R Activating Dd, Dk, Ld  
Ly49S Inhibitory ?  
Ly49T Inhibitory ?  
Ly49U Activating ?  
Ly49V Inhibitory Db, Dd, Kk  
Ly49W Activating Dd, Kk  
* To date no full length transcript have been found 
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These receptors are disulfide–bound homodimers, type II trans-membrane 
proteins with C-type lectin-like domains.  Ten of these appear to be activating 
receptors, of which some bind MCH class I molecules while others recognize 
MHC–like molecules produced by viruses.  For example Ly49H recognizes m157 
molecules produced by murine cytomegalovirus infected cells.288,289  Ly49 
activating receptors contain no ITIM motif and do not seem to become 
phosphorylated upon engagement with ligand.  Instead they necessitate the 
interaction with ITAM-containing adapter molecule to exert their effect, such as 
death adapter protein 12 (DAP12),290 CD3ζ,291 DAP10,292,293 and FcεRIγ,294 the 
latter being responsible for binding to CD16 and stimulate antibody-dependent 
cellular cytotoxicity (ADCC).295  DAP12 is a 16kDa protein with an aspartic acid 
residue in its transmembrane region, which can interact with the asparagine on 
Ly49D transmembrane region upon its engagement.296  After this interaction, 
tyrosine in the ITAM of DAP12 becomes phosphorylated,297 which leads to a 
activation of signaling events involving the phosphorylation of Syk, PLCy-1 and 
calcium mobilization.290,296  It was also shown that the SH2 domain of Syk can 
interact with DAP12 phosphorylated tyrosine.296,297  The activation and/or 
phosphorylation of these effector molecules will lead to the release of perforin, 
granzyme and cytokines to kill the target cell and stimulate a complete immune 
response. 
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The activation of NK cells has to be counterbalanced by inhibitory 
signaling in order to prevent inadvertent attack of host cells.  To this effect, NK 
cells rely on the presence of inhibitory receptors that recognize MHC class I 
molecules on host’s cells such as receptors of the Ly49 receptors family.  The 
inhibitory receptor Ly49A was the first one to be cloned from the NK cell gene 
complex.298  The human counter part of the Ly49 inhibitory receptors are the 
killer cell inhibitory receptors (KIRs), which belong to the Ig superfamily.299  KIRs 
and Ly49 receptors evolved separately into totally different molecules that both 
have the ability to negatively control NK cell activation through recognition of 
MHC Class I molecules.  Furthermore, they both exhibit a cytoplasmic ITIM 
sequence, and both were observed to associate with Shp-1 and/or Shp-2 after 
engagement, leading to inhibitory signaling.300,301 
 
Like human KIRs, murine Ly49 receptors such as Ly49 A, C, G2 and I, 
have a cytoplasmic ITIM motif that becomes tyrosine-phosphorylated upon 
engagement by self MHC class I molecules.302-304  The murine ITIM sequence 
was first identified as a 13 amino acid sequence on FcγRIIB receptor necessary 
for inhibitory function.305,306  ITIMs are now know to be present in several 
receptors involved in immunological processes and are usually composed of 6 
amino acids (I/V/L/S)-X-Y-X-X-(L/V).307  Upon engagement of inhibitory 
receptors, such as Ly49A and G2, the tyrosine residue in the ITIM becomes 
phosphorylated and can then recruit molecules that contain a SH2 domain such 
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as Shp-1308 and possibly Shp-2.309  Once activated, these molecules can then 
dephosphorylate and therefore deactivate Syk, PLCγ-1/2, ZAP70, and Shc, which 
would participate in the stimulation of cytotoxic response.310  These inhibitory 
receptors are responsible for preventing unwanted attack against host cells, 
however, once an infected or cancerous cells down-regulate expression of their 
MHC class I molecule, Ly49 inhibitory receptors can not be engaged and NK 
cells are then free to kill.  This process was first described by Karre and his 
colleagues, who observed that an H-2B deficient lymphoma was rejected by the 
host, while a lymphoma that expressed MHC molecules would engraft in the 
host.  They named this concept the “missing-self hypothesis” (Figure 26).311  It 
was later confirmed by other groups who noticed that β2-microglobulin deficient 
cells would get rejected by irradiated MHC-matched mice while β2-microglobulin 
expressing cells could engraft successfully.312,313  These studies relate that NK 
cells will be inhibited from killing a possible target cell when this one expresses 
the right MHC molecules.  The MHC molecules bind inhibitory receptors on NK 
cells, which then block activation pathway. 
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Figure 26.  Missing-self hypothesis.  Graphic representation of the possible outcomes 
when a NK cell encounters a possible target cell.  MHC class 1 or non-MHC class I 
molecules expressed by the host can be recognized by inhibitory receptors on NK cells, 
dampening the possible response of NK cells. The level of activation and inhibitory 
signal received by the NK cell, and the qualitative difference in the signal transduced will 
determine the NK cell response.  Loosely adapted from Lanier review on NK cells 
published in 2005.314 
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SHIP and NK Cell Development 
 
The transcriptional regulation of Ly49 receptors remains to be fully 
elucidated.  Why is their expression variegated?  Why do certain subset of NK 
cells in the same individual express different but overlapping Ly49 receptors on 
their surface?  Right before the proliferation phase, immature NK cells, which 
already express NK1.1 and the CD122 (IL-2 and IL-15 receptor β) receptor, 
acquire CD94-NKG2 and Ly49 receptors.315  Thus, it is possible that upon 
acquisition of the Ly49 receptors, the cell subset that bear Ly49 engaged by the 
host MHC Class I molecules would be prompt to survive or proliferate.  To this 
end, the Ly49 receptors specific for the host MHC molecule would guide the 
proliferation and survival of the NK cell subset that expresses it.  Consistent with 
this hypothesis, the p85 subunit of PI3K can be recruited to the membrane by 
inhibitory Ly49 receptors to promote formation of PI(3,4,5)P3.  Even though that 
molecule has been implicated in the simulation of NK cells through activation of 
PLCy, it is possible that PI(3,4,5)P3 recruit the PH containing protein AKT, which 
will promote survival and proliferation of the cell.  Since SHIP contains an SH2 
domain, it could be recruited to the membrane by Ly49 receptor phosphorylated 
ITIM motifs, where it would negatively control the survival and/or proliferation 
signal received by NK cells through dephosphorylation of PI(3,4,5)P3.  This event 
would prevent over-representation of a certain subset of receptors, thus, 
maintaining a proper repertoire of Ly49 receptor on NK cells. 
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Aims:: 
1) Define the NK cell compartment in SHIP-/- mice.  
2) Identify factors contributing to the disruption of NK cell receptor repertoire. 
 
Results 
 
Spleen of SHIP-/- Have Increased Number of NK Cells 
 
Analysis of the NK compartment in the spleen at different stages of 
ontogeny indicated that NK cells develop normally in juvenile SHIP-/- mice (Figure 
27Ai, B).  However, in SHIP-/- adult mice an abnormal population of NK cells 
appears that exhibit a 10-fold increase in the surface expression level of the NK 
receptor, NK1.1 (NK1.1hi), as compared to WT controls (Figure 27Aii, Aiii).  The 
NK1.1hi population lacks CD3 and thus is not an NK-T cell population.  The 
appearance of the NK1.1hi population coupled with an increase in NK cells with a 
normal 2B4+NK1.1+ staining profile (NK1.1+ cells) leads to a 2 to 3-fold increase 
in peripheral NK cells in SHIP-/- adult mice (≥8 weeks), relative to wild-type 
littermates (Figure 27B). 
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Figure 27.  Increased NK cell numbers in SHIP-/-.  (A) FACS analysis of splenic NK cells 
in SHIP+/+ and SHIP-/- littermates at different stage of ontogeny, at (i) 3, (ii) 5, and (iii) 8 
weeks.  Genotype and age of the mice at the time of sacrifice and analysis are 
indicated.. (B) Absolute splenic NK cell numbers in SHIP+/+ and SHIP-/- mice at 
different ages.  Significance was established using the unpaired student t test (Prism 4).  
(mean ± SEM, n≥3).  The values determined for SHIP-/- mice that are significantly 
different from that of their age-matched SHIP+/+ counterparts are indicated by the 
following symbols: +p<0.05 and,* p<0.01. Collaboration with J. Howsen, T. Ghansah 
Ph.D., S. May and K.HT Paraiso MS. 
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Murine NK cells detect MHC class I molecules using receptors encoded 
by the Ly49 or CD94/NKG2 genes.316  Expression of these MHC receptors is 
distributed among different NK subsets during the transition from neonate to 
adult.  Because the number of peripheral NK cells increases in SHIP-/- mice 
during this period, we asked whether the relative representation of NK subsets 
expressing certain Ly49 and CD94 receptors might account for this increase.  
Indeed, the relative representation of several Ly49 receptors and CD94 was 
significantly altered in the SHIP-/- NK compartment of older mice when compared 
to SHIP+/+ littermates (Figure 28).  However, SHIP-/- weanlings, at 3 weeks of 
age, showed no skewing of their NK repertoire relative to wild-type littermates 
(Figure 28).   
 
The NK cell receptor repertoire distortion was most pronounced in mice ≥8 
weeks of age and was found in both the NK1.1+ and the NK1.1hi populations.  We 
found that Ly49A+ and C/I+ NK cells were overrepresented in adult SHIP-/- mice, 
while Ly49D+, G2+ and CD94+ were underrepresented (Figure 28).  Because the 
overwhelming majority of the NK1.1+ and NK1.1hi cell populations lacked Ly49I in 
adult SHIP-/- mice, the majority of the Ly49C/I+ NK cells express only Ly49C.  
Thus, the repertoire distortion in adult SHIP-/- mice leads to an NK compartment 
dominated by a subset of cells expressing Ly49A and/or Ly49C, where Ly49D, 
G2, I can CD94 are underrepresented (Figure 28).  In vitro and in vivo studies 
indicated that Ly49A and Ly49C can bind ligands in the H2b haplotype of SHIP-/- 
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mice; however, these two receptors also bind and transmit inhibitory signals from 
ligands in most or all H2 haplotypes.317-320  Therefore, SHIP deficiency leads to 
an NK inhibitory repertoire that is both, self-specific and promiscuous for other 
ligands. 
 
A potential explanation for the repertoire disruption seen in SHIP-/- NK 
cells is that SHIP is recruited to certain inhibitory receptors expressed by NK cells 
to oppose intracellular signals that mediate survival of specific NK subsets 
expressing these receptors. Indeed, SHIP binds the phosphorylated ITIM motif of 
Ly49A in vitro.42 These findings prompted us to examine whether SHIP 
associates in vivo with Ly49 receptors expressed by NK cells. 
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Figure 28.  MHC class I receptors on peripheral NK cells in SHIP-/- mice.  The mean 
percentage of peripheral NK cells expressing the indicated Ly49 or CD94 molecule after 
gating on 2B4+NK1.1+ cells. The age and genotype of the mice are indicated.  
Significance was established using the unpaired student t test (Prism 4).  (mean ± SEM, 
n≥3).  Values determined for SHIP-/- mice that are significantly different from their age-
matched SHIP+/+ littermates are indicated: +p<0.05; * p<0.01. Collaboration with J. 
Howsen, T. Ghansah Ph.D., S. May and K.HT Paraiso MS. 
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SHIP is found associated with Ly49 receptors where it may control the level of 
PI(3,4,5)P3 generated by PI3K and negatively regulate Akt phosphorylation 
 
Analysis of potential SHIP interaction with different Ly49 receptors, 
revealed that SHIP is associated with Ly49A and Ly49C under physiological 
conditions (Figure 29A), but not with Ly49G2, Ly49F, or Ly49I (Figure 29B).  As 
further confirmation that the protein co-precipitating with Ly49A and Ly49C is 
SHIP, we analyzed NK lysates from SHIP+/+ and SHIP-/- mice (Figure 29C).  
 
This analysis detected co-precipitation of SHIP with Ly49A and Ly49C only 
in the SHIP+/+ NK lysates, confirming the specificity of the Western Blot.  
Because SHIP limits the in vivo survival of myeloid cells by opposing the 
PI3K/Akt pathway,2,3 we examined whether Akt is activated in SHIP-/- NK cells in 
vivo based on its phosphorylation at Thr308.321,322  We found that both Akt 
phosphorylation and total Akt protein levels were significantly increased in SHIP-/- 
NK cells relative to those in SHIP+/+ NK cells (Figure 29D). The increase in total 
Akt levels is surprising; however, primary B cell activation leads to increased Btk 
levels in a PI3K-dependent manner.323 This additional level of regulation may 
further amplify signals from PH domain-containing kinases, such as Akt or Btk, 
which are recruited to PI(3,4,5)P3.  Taken together, these findings suggest the 
interplay of SHIP and PI3K may influence the relative survival of NK subsets 
expressing Ly49 receptors capable of recruiting these enzymes. Interestingly, 
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PI3K is recruited to human KIR and can activate Akt in human NK cells.324  Thus, 
despite their evolutionary divergence in how they bind MHC class I molecules, 
murine Ly49 receptors and human KIR may recruit SHIP to limit the in vivo 
survival of NK subsets, just as both receptors recruit Shp-1 to limit NK effector 
functions.310,325 
 
 
Figure 29.  SHIP is recruited to NK inhibitory receptors in vivo to oppose activation of 
Akt.  (A) Western blot detection of SHIP in Ly49A and Ly49C immunoprecipitates. 
Immunoprecipitation with a murine IgG2a antibody (IgG2a) was analyzed as a negative 
control and SHIP was immunoprecipitated as a positive control (SHIP). (B) Western 
blotting for SHIP in other Ly49 immunoprecipitates (Ly49G2, Ly49F, and Ly49I). (C) 
Western blot analysis of SHIP in Ly49A and Ly49C immunoprecipitates prepared from 
lysates of SHIP+/+  (+/+) and SHIP−/− (−/−) NK cells. (D) Western blot analysis of Akt 
phosphorylation at Thr308 and total Akt protein in SHIP+/+ and SHIP−/− NK cell lysates. To 
control for equal loading the blot was re-probed with antibodies specific for β-actin, 
GAPDH, and α-tubulin.  Collaboration with T. Ghansah Ph.D., and K.H.T Paraiso MS. 
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DAP12 is Expressed by SHIP-/- BM Cells and NK Cells 
 
According to our data, the disruption in NK cell receptor repertoire in 
SHIP-/- mice appears to result from a bias towards selection for Ly49A and C 
receptors, due to their increased survival.  Consequently, the level of Ly49D+ NK 
cells in SHIP-/- mice is decreased was compared to WT mice.  However, we 
wanted to determine if the decrease in Ly49D+ NK cells representation did not 
arise from a lack of DAP12 expression.  It has been shown that Ly49D and other 
activation receptors require the presence of DAP12 to migrate to the cell 
surface.326  Thus, we considered the possibility that Ly49D was not found on the 
surface of SHIP-/- NK cells due to the absence of its adaptor molecule DAP12.  
However, using reverse-transcription PCR (RT-PCR), we observed that DAP12 
is expressed in SHIP-/- BM (Figure 30A) and SHIP-/- NK cells as well as WT 
(Figure 30B).  Another molecule known to be involved in transduction of extra-
cellular signaling by NK cell receptors is DAP10.  Like for DAP12, we also 
observe that SHIP-/- and WT BM cells express the DAP10 adaptor molecule 
(Figure 31).  Since we can detect DAP12 by RT-PCR it suggests that Ly49D 
receptors should reach the SHIP-/- NK cell if they were to be expressed. 
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Figure 30.  DAP12 is expressed in SHIP-/- and WT BM cells and NK cells.  RNA from (A) 
BM and (B) NK cells was isolated and RT-PCR was performed to assess the presence 
of DAP12. 
 
 
 
 
Figure 31.  DAP10 is expressed in SHIP-/- and WT BM cells.  RNA from BM cells was 
isolated and RT-PCR was performed to assess the presence of DAP10. 
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SHIP but not Shp-1 is Found Associated with Ly49A under Physiological 
Conditions 
 
Signal transduction studies on NK cells have relied for a long time on the 
study of lymphokine-activated killer (LAK) cells.  These cells are splenocytes that 
are grown for approximately 7 days in a media containing a combination of 
cytokines that promote NK cells proliferation.  After this 7-day culture, the cells 
are collected and activation experiments are performed.  Several group observed 
that when LAK cells were treated with pervanadate, Shp-1 was recruited to the 
tyrosine-phosphorylated ITIM sequence of Ly49A molecule.308  Once to the 
membrane, Shp-1 can dephosphorylate molecules such as Syk, PLCγ-1/2, 
ZAP70, and Shc,42,310 leading to their deactivation, preventing NK cell from killing 
target cells.  Instead of culturing the cells for 7 days, we studied the biology of NK 
cells right after isolation, which would be closer to physiological condition.  In this 
experiment we observe that SHIP does co-immunoprecipitate with Ly49A, while 
Shp-1 does not (Figure 32A, B).   This confirms that the roles of SHIP and Shp-1 
in NK cell biology are very different (Figure 33).  While Shp-1 appears to be 
important for the control of activation signaling after Ly49 engagement, SHIP 
seems to play a role in NK cell homeostasis and maintenance of receptor 
repertoire. 
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Figure 32.  SHIP but not Shp-1 is recruited to NK inhibitory receptor Ly49A in vivo.  (A) 
Western blot detection of SHIP in Ly49A IP, Ly49G, a murine IgG2a antibody (IgG2a) IP 
used as a negative control. WCL from 70Z/3 and NK cells (same lysate than the one 
used for IP) were used as positive control.  (B) Western blot detection of Shp-1 in Ly49A 
IP, Ly49G, a murine IgG2a antibody (IgG2a) IP used as a negative control.  WCL from 
A431 and NK cells (same lysate than the one used for IP) were used as positive control. 
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Figure 33.  Signaling pathways downstream of Ly49A and C that can be influenced by 
SHIP in NK cells.  As shown on this schematic representation of NK cells signaling 
pathways.  SHIP, by being recruited to Ly49A and C can negatively control the survival 
and proliferation of NK cells in response to encounter with self H2b encounter.  Once NK 
cell activation receptors are also engaged, Shp-1 will be recruited to the membrane to 
Ly49 receptors, where it will dephosphorylate kinases that, when activated, trigger an 
attack on target cells. 
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Discussion 
Our study shows that F4 SHIP-/- mice have an increased number of 
peripheral NK cells, and that their receptor repertoire is disrupted.  This suggests 
that NK cells might undergo some sort of selection process once they acquire 
their Ly49 receptors during development.  The interaction of these NK cell 
inhibitory receptors with self MHC ligands may elicit signals that promote the 
survival or proliferation of these cells in vivo.327  Thus, NK cells could be selected 
for their ability to be engaged by host MHC molecule (Table 3), which would 
ensure that the NK cells in an organism express the proper inhibitory receptors to 
prevent unwanted attack on self.  SHIP, once recruited to the membrane by 
some of these Ly49 receptors could negatively regulate their survival and 
proliferation by controlling signaling pathways downstream of PI3K. 
 
Alternatively, SHIP could be recruited to the membrane by Ly49 receptors 
to participate in the control of NK cell activation, as it has been shown to 
negatively control calcium influx in mast cells.99,241  In addition, PI3K276,277 and 
PLCy molecules278-280 have been shown to play a role in NK cell activation.  
Since SHIP has the potential to dephosphorylate PI(3,4,5)P3, it could downregulate 
these signaling pathways.10,56-59,62,63  However, this scenario seems highly 
unlikely since SHIP-/- NK cells are unable to kill allogeneic transplant43 and are 
not as efficient as WT NK cells in lysing target cell in an in vitro assay.43   
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On the other hand, SHIP is known to control signaling pathways 
downstream of cytokine receptors that can lead to activation of transcription 
factors, which could potentially impact Ly49 expression.328,329  Up to this date the 
transcription regulation of NK cells receptors, including Ly49 receptors, appears 
to be highly stochastic with each receptor gene containing up to 3 separate 
promoters.330  Thus, more studies are necessary to understand the mechanism 
for Ly49 variegated gene expression.  Interestingly, NFκB has been implicated in 
the regulation of the probabilistic switch regulating Ly49 receptors expression.331  
Knowing that SHIP can impact NFκB activation,332 SHIP-deficiency could perturb 
Ly49 transcription regulation.  Interestingly, PLCγ2-/- mice also have a disrupted 
Ly49 receptor repertoire.279  This suggests that pathways downstream of PI3K 
are important for the establishment of a proper Ly49 receptor repertoire. 
 
Materials and Methods 
 
FACS Analysis of the NK Cell Compartment and their Receptors 
 
To analyze the peripheral NK cell compartment spleens were collected 
from mice at various ages.  A single cell suspension was prepared by crushing of 
the spleen with a syringe plunger, and NH4Cl lysis (Red blood cell lysis buffer, 
eBioscience) of erythrocytes.  The cells were then stained with an antibody 
against the Fc receptor to prevent unspecific binding.  All antibodies were from 
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BD Biosciences, except where mentioned.  For the NK cell compartment 
assessment, splenocytes were stained with fluorescently conjugated antibody 
against the NK-associated markers 2B4-PE, NK1.1-FITC and CD3-APC.  The 
cells were then incubated into a solution of 7AAD (5 μl per 1 million cells) for 
dead cell exclusion.  Data acquired on FACS Calibur with CellQuest software, 
and analyzed with FlowJo.  For the receptor repertoire analysis, isolated and Fc 
blocked splenocytes were stained with 2B4, NK1.1 and anti-Ly49A (A1), -Ly49C/I 
(5E6), -Ly49D (4E5), -Ly49G2 (4D11) or -CD94 (eBioscience).  To distinguish 
Ly49C staining from Ly49I, cells were stained with NK1.1, Ly49C/I and Ly49I 
(YLI90). All biotin conjugates were revealed by Streptavidin-APC (eBioscience).  
Cells were then exposed to 7AAD for dead cell exclusion and data was acquired 
on FACS Calibur with CellQuest software, and analyzed with FlowJo.
 
Protein Lysis Buffers 
 
Radioimmunoprecipitation (RIPA) buffer.  The modified RIPA buffer 
protocol was obtained from the Upstate catalog.  To prepare 100 ml of RIPA 
buffer, add 790 mg of Tris base (Fisher) to 75 ml of distilled water, add 900 mg of 
NaCl (Fisher), adjust the pH to 7.4 with HCl, then add 10 ml of 10% NP-40, 2.5 
ml of 10% Na-Deoxycholate and 1 ml of 100 mM EDTA, adjust the final volume 
to 100 ml with distilled water and store at 4oC until use.  Right before using the 
buffer add protease and phosphates inhibitors to it.  A cocktail of protease 
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inhibitors from Sigma-Aldrich was used at a concentration of 0.1%, or 10 μl of 
protease inhibitor cocktail in 1 ml of RIPA.  For phosphates inhibitor, we use 
pervanadate (NaVO3) to a final concentration of 1mM, thus add 10 μl of 100mM 
NaVO3 to 1 ml of RIPA buffer. 
 
Digitonin cell lysis buffer.  First, weigh 0.5 g digitonin (CalBiochem, EMD 
Biosciences, Inc., San Diego, CA, USA) into a 50 ml tube add 25 ml ddH2O and 
boil for about 2 h.  Allow to cool on the bench and if a precipitate forms, boil 
again for longer period of time, until no more precipitates are found after cooling.  
Then, add the following reagents: 0.6 ml of 10 % Triton X-100, 1.5 ml of 5 M 
sodium chloride (NaCl), 10 ml of 100 mM Triethanolamine, pH 7.8, 125 μl of 1 M 
calcium chloride (CaCl2), 50 μl of 1 M magnesium sulfate (MgSO4), 25 μl of 20 % 
Sodium Azide and top with ddH2O to 50 ml.  As for the RIPA buffer, the protease 
and phosphatases inhibitors were added right before use.  Immunoprecipitation 
was carried as mentioned in the next section.  After immunoprecipitation, the 
precipitated beads were washed 4 times with a solution that prevents (or 
diminishes) the detection of unspecific interaction.  This washing buffer 
surnamed FROPS buffer contains 30 ml of 5 M NaCl, 5 ml of 1M CHAPS, 50 ml 
of 1 M Tris pH8 brought up to 1 liter using deionized distilled water. 
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Biochemical Analysis of SHIP and Akt 
 
NK-enriched C57BL6/J splenocytes were prepared by depletion of B cells 
and macrophages by adherence to nylon wool followed by T cell depletion using 
anti-CD3 plus complement. NK cells were then lysed in modified RIPA buffer or 
digitonin buffer.  Prior to immunoprecipitation the NK cell lysates were pre-
cleared twice by incubation with 0.25 μg of an murine or rat IgG2a antibody (BD 
Biosciences) and 50 μl of Protein A-Agarose or Protein G-Sepharose beads 
(Upstate, Charlottesville, VA, USA). The beads were pelleted at 15,000 RPM for 
15 minutes at 4°C. The pre-cleared supernatants were immunoprecipitated with 2 
μg of anti-Ly49A (A1), -Ly49C/I (5E6), -Ly49F (HBF-719), -Ly49G2 (4D11), -
Ly49I (YLI-90) or IgG2a (BD Biosciences).  To pre-clear the lysate and as a 
negative control for immunoprecipitation, mouse IgG2a was used for Ly49A and 
Ly49C/I immune precipitates, rat IgG2a was used for Ly49G2 immune 
precipitates, and mouse IgG1 was used to for Ly49F and Ly49I immune 
precipitates. Immune complexes were precipitated by addition of 50 μl of Protein 
A-Agarose (Ly49A, Ly49C/I) or Protein G-Sepharose (Ly49F, Ly49G2, Ly49I) 
beads. The immunoprecipitates were resolved on a 4-12% Tris-Bis 
polyacrylamide gel and transferred to a nitrocellulose membrane (Amersham 
Pharmacia, Piscataway, NJ). The filters were then probed with a 1:1000 dilution 
of anti-SHIP (P2C6, a kind gift of Larry Rohrschneider) and a horseradish 
peroxidase (HRP)-conjugated anti-mouse IgG secondary antibody (Amersham 
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Pharmacia) at a 1:80,000 dilution.  The presence of SHIP was revealed using the 
SuperSignal West Femto reagent (Pierce Biotechnology Inc., Rockford, IL, USA).  
The results of the Ly49 immunoprecipitations in Figure 29 and 32 are 
representative of three independent analyses of NK-enriched splenocytes. For 
analysis of Akt activation lysates of purified NK cells from the spleens of SHIP-/- 
and SHIP+/+ were prepared as above.  Equal quantities of protein from cell 
lysates prepared from SHIP+/+ and SHIP-/- NK cells were resolved on a 4-12% 
Tris-Bis polyacrylamide gel (Novex/Invitrogen, Carlsbad, CA, USA), transferred 
to a nitrocellulose membrane (Amersham Pharmacia) and the filters probed with 
an anti-Phospho-Akt(Thr308) antibody (Cell Signaling Technology, Danvers, MA, 
USA) at a 1:1000 dilution.  The presence of Akt was detected by a HRP-
conjugated donkey anti-rabbit IgG secondary antibody (Amersham Pharmacia) at 
a 1:2000 dilution and revealed using ECL substrate (Amersham Pharmacia). The 
blot was then stripped and reprobed in a similar manner using anti-β-actin (Cell 
Signaling Technology), anti-GAPDH (Research & Diagnostics Antibodies, 
Benicia, CA) and anti-α-tubulin (Oncogene Research, Cambridge, MA) as 
internal controls for protein loading. The detection of increased Akt levels and its 
activation is representative of three separate analyses of NK cell lysates from 
SHIP-/- and SHIP+/+ mice. 
 
122 
  
RT-PCR for DAP10 and DAP12 
 
Cells were isolated as mentioned above.  For the NK cells RNA extraction, 
splenocytes were first treated with Fc block (CD16/CD32) for 15 minutes to 
prevent unspecific binding.  The cells were then exposed to NK1.1-FITC (NK1.1) 
and CD3ε-PE (145-2C11).  The FACS Vantage with the DiVa software was then 
used to sort CD3-NK1.1+ or CD3-NK1.1++ cells in the presence of 7AAD to 
exclude to dead cells.  All antibodies were from BD Biosciences.  RNA was 
isolated following the protocol for the RNAqueous-4PCR kit (Ambion, Austin, TX, 
USA).  RT-PCR was performed using MultiScribe reverse transcriptase (Applied 
Biosystems, Foster City, CA, USA) protocol.  Briefly, 5xRT-PCR buffer (4 μl), 25 
mM MgCl2 (2 μl) 10 mM dNTP (2 μl), RNase inhibitor (0.5 μl), 100 mM DTT (2 μl) 
and random hexamers (0.5 μl), were mixed with RNase free water (up to 20 μl) 
and RNA isolated from tested samples (equivalent of 10 000 cells).  The enzyme, 
0.3 μl of MultiScribe RTase was then added to the reaction right before starting 
the reverse transcription on a Px2 thermal cycler PCR machine (Thermo Electron 
Corporation, Waltham, MA) using the following program; 10 minutes at 25oC and 
12 minutes at 42oC.  The RT-PCR products were then placed at 4oC for 1-2 
hours.  10 μl of the RT-PCR reaction was then used for a PCR reaction using the 
primers for specific genes.  Briefly, cDNA (10 μl), RNase free water (25 μl), 5x 
AmpliTaq buffer, (8 μl) 25 mM MgCl2 (2.5 μl), 10nM dNTP (3 μl), 20 μM DAP12 
forward and reverse primers (.5 μl each) and 0.5 μl of AmpliTaq (Applied 
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Biosystems) were mixed then PCR reaction was performed.  PCR reaction was 
done on Px2 thermal cycler PCR machine using the following program; 10 
minute polymerase activation at 95oC, 43 cycles of 25 second at 94oC and 1 
minute at 60oC, and then a final incubation at 72oC for 7 minutes.  The expected 
PCR product for DAP12 was 120 nucleotides and the band on the 1.2% agarose 
gel appears to be 120.  When the PCR was performed for DAP10, DAP 10 
forward and reverse primers were used for the PCR reaction, otherwise every 
thing else was as mentioned earlier, a 126 base pairs sequence was expected, 
as seen on the 1.2% agarose gel.  Primers used for DAP10: Forward: 5’-caa gtc 
aga cat cgg cag gtt c-3’ and Reverse; 5’-gca tac ata caa aca cca ccc cta-3’.  
Primer used for DAP12 Forward: 5’- cct tcc tgt cct cct gac tgt g and Reverse 5’-
tca ccc aga aca atc cca gc-3’. 
 
Western Blot for Shp-1 
 
Lysis and immunoprecipitation was carried as mentioned above.  The 
same immunoprecipitate was then loaded on two different gels, one for Western 
blot with SHIP and the other one with Shp-1.  The Western Blot and probing for 
SHIP was performed as mentioned above.  The membrane to be probed for Shp-
1 was then blocked in 5% non fat milk (NFM) in TBS (TBS-5%NFM) for 20 
minutes at RT with constant agitation.  The membrane was then incubated 
overnight at 4oC in TBS-5%NFM containing 1 μg/ml of anti Shp-1 antibody 
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(Upstate).  The morning after the membrane was washed twice in distilled water 
and incubated for 1.5 hour at RT in TBS-5%NFM containing HRP conjugated 
anti-rabbit antibody (Cell Signaling Technology) at a concentration of 1:80,000.  
The membrane was then washed twice in distilled water, and once in TBS-0.05% 
Tween 20 for 5 minutes.  The membrane was washed another 5 x in distilled 
water and revealed using the SuperSignal West Femto for 5 minutes (Pierce 
Biotechnology Inc.). 
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Section IV: Murine ES Cells and s-SHIP 
Introduction to ES Cells 
 
Murine ES (mES) cells are pluripotent cell lines derived from the culture of 
preimplantation embryos or epiblasts.333-335  These cells have the potential to 
differentiate into any cells of an organism.  ES cells, contrarily to cells from 2-
cells-stage embryo, can not form the trophoblast, and therefore, should be 
referred to as pluripotent and not totipotent.336  ES cells can be derived and 
grown for several passages, without any intervention or immortalization agent.  
Throughout this process ES cells do not undergo senescence and retain their 
diploid karyotype.  They can multiply in the absence of serum, if in the presence 
of feeder layer, and are not subject to contact inhibition or anchorage 
dependence.337  Once ES cells are injected into a developing blastocyst, they 
have the potential to integrate that blastocyst and change parts of its genetic 
background.  Successful integration of ES cells into blastocyst results in the 
colonization of germ cells.337  These mice are then considered chimeras and can 
produce functional gametes containing the genetic background of the injected ES 
cells.  Thus, ES cells have a tremendous potential to be used as a vehicle for 
introducing genetic modification in mice and many other organisms.  It is 
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important to note that injection of ES cells in adult mice has been associated with 
the formation of teratocarcinoma.334  The maintenance of ES cells in vitro is 
paramount for the development of genetic manipulation strategies, therefore 
understanding the process of self-renewal versus differentiation is very important. 
 
The first mES cell lines were derived by growing these cells on fibroblast 
feeder layers.  However, the presence of these feeder cells made the study of 
mES cell signaling very difficult.  Then, Smith and Hoopers found that mES cells 
could be grown, undifferentiated, in the presence of FBS and LIF.338-340  
Furthermore, it was established recently that signaling by bone morphogenetic 
proteins (BMP) works together with LIF to maintain the pluripotency of mES 
cells.341,342 
 
ES Cells Signaling Pathways 
 
LIF and ES cells.  In mES cells, LIF, coming from the feeder layer or given 
in the culture media as a recombinant protein, appears to be essential for the 
maintenance of ES cell pluripotency.338-340  LIF is a factor that belongs to the IL-6 
cytokine family, which also includes IL-11, ciliary neutropic factor, oncostatin M 
and cadiotrophin-1.343  LIF engages the heterodimerization of receptor complex 
composed of LIFr and gp130, gp130 being a common receptor subunit of the IL-
6 cytokine family receptor.344,345  The heterodimerization of this complex leads to 
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activation of janus associated kinases (JAKs) that phosphorylate the receptor 
chain (Figure 34). 
 
 
Figure 34.  LIFR/gp130 receptor complex signal transduction pathways and how s-SHIP 
may impact them in pluripotent stem cells.  Based on research from several groups, it 
was found that the LIFR/gp130 receptor complex can impact ES cell self-renewal and 
differentiation.337,346-348  Although s-SHIP does not become phosphorylated after LIF 
stimulation, s-SHIP is constitutively present at the membrane and thus can impact the 
signaling pathways downstream of ES cell receptors.  As illustrated above, LIFR/gp130 
has the potential to trigger either differentiation or self-renewal depending on which 
downstream signaling components are activated. 
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The phosphorylated tyrosine on LIFr/gp130 complex can then serve as 
anchor site for SH2 containing domains.  Some of the molecules recruited to the 
activated LIF/gp130 receptor complex consist of signal transducer and activator 
of transcription 3 (STAT3),349 PI3K,350 Erk,337,351 and Shp-2.352,353  These proteins 
can then be activated by surrounding kinases354-356 and exert their effect.  
Interestingly, the activation and formation of protein complexes between these 
different proteins create a very fragile balance between self-renewal vs. 
differentiation during proliferation signaling.337 
 
STAT3 stimulates ES cell self-renewal.  In mES cells, LIF predominantly 
activates STAT3,349 and it appears to be essential for self-renewal (Figure 34).357  
Consequently, down regulation of STAT3 through expression of a dominant 
negative protein causes ES cell to differentiate. Studies using a chimeric STAT3 
molecule directly activated by estradiol showed that STAT3 is not only necessary 
but might even be sufficient to block differentiation of mES cells.358 
 
 
ERKs antagonize ES cell self-renewal.  While recruitment of STAT3 to the 
activated LIFr/gp130 leads to self-renewal of ES cell, recruitment of Shp-2 and 
Grb2 will lead to stimulation of the Erk1/2 (p42/44) and differentiation of ES cells 
(Figure 34).346  Attenuation of ERK and Shp-2 signaling (by pharmacological 
inhibition of MAPK or by overexpression of Erk phosphatase) result in an 
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increase in self-renewal by reduction of differentiation.347  However, inhibition of 
ERK does not replace the Stat3 requirement but enhances its action (direct or 
indirectly) in the promotion of ES cells self-renewal.347  The balance between 
these two major signaling pathways is important for ES cells maintenance.  Once 
phosphorylated, LIFr/gp130 receptor can recruit SH2 domain containing protein 
such as Shp-2.352,353,356  Grb2 will then bind Shp-2, which will result in the 
recruitment of SOS to the membrane.  Once SOS is at the membrane, it can then 
activate RAS/RAF/MAPK/Erk and downstream transcriptional factors such as, 
Myc, Ets, Elk, and SRF.359 
 
Furthermore, Shp-2 also associates with Gab1, which can recruit PI3K.360  
The resulting phospholipids, PI(3,4,5)P3, can then provide a binding site for the PH 
domain of Gab1, stabilizing the association of Shp-2/Gab1/Grb2/Sos complex at 
the membrane and facilitating coupling to RAS signaling pathway (Figure 34).361  
However, the production of PI(3,4,5)P3 can also promote the recruitment of 
molecules that can increase survival or proliferation of the cells, such as Akt, 
which has been shown to stimulate ES cell self-renewal.362 
 
 
Since SHIP, has been implicated in the control of several of these 
signaling pathways, s-SHIP might also impact some of these pathways.  Even if 
s-SHIP lacks the SH2 domain and does not appear to bind Shc, it does bind 
Grb2 and might be involved in the control of protein complex formation of 
Grb2/Shp-2/Gab1/Sos, which leads to differentiation stimulation.49  Furthermore, 
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s-SHIP has been shown to be constitutively located at the membrane49 where it 
could hydrolyze the 5’ phosphate of PI(3,4,5)P3363 and dampen signaling 
downstream of PI3K, such as Akt or Gab1 activation. 
 
PI3K signaling in ES cells.  Inhibition of PI3K using drug inhibitor or 
dominant negative delta85, led to a decrease in Akt, GSK3alpha/beta, and S6 
proteins activity and an increase in Erk phosphorylation, resulting in a reduction 
of self-renewal.350  One of the lipid phosphatases responsible for degradation of 
PI(3,4)P2 and PI(3,4,5)P3 levels, is PTEN.  In fact, PTEN-/- ES cells have enhanced 
viability and rate of cell proliferation, correlated with increased level of PI(3,4,5)P3 
and phosphorylation of Akt, and inactivation of Bad (a pro-apoptotic protein).364  
The absence of PTEN results in an increased cell division rate, which is much 
more important in ES cells than in fibroblasts, suggesting that PI3K signaling is 
more important in ES cells than fibroblast.337  Even though PTEN appears to be 
primarily responsible for PI(3,4,5)P3 degradation and down modulation of PI3K 
effector signaling pathways in ES cells, s-SHIP could also have a role in this 
process. 
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s-SHIP 
 
s-SHIP is a predicted 104/97kDa protein that is expressed by ES cells and 
HSC but not  normal lineage differentiated cells.43  s-SHIP can be amplified  by 
RT-PCR using primers that span the carboxyl terminal end of SHIP but not by 
primers that bind the amino terminal region.49  This is explained by the fact that s-
SHIP sequence lacks the SH2 domain found in full-length SHIP.49 
 
 
Studies revealed that s-SHIP is the murine homologue of human SIP-110.  
Similar to s-SHIP, SIP-110 is a 109kDa SHIP isoform protein that lacks the SH2 
domain.4  We observed that the first exon of SIP-110 and s-SHIP share 82% 
homology.  Furthermore, s-SHIP has a 44 nucleotides sequence in its amino 
terminus that is not present in SHIP cDNA, this region was named stem-SHIP 
region (SSR).49  In SIP-110, a similar 42 nucleotides SSR-like sequence is 
observed.49  In our paper, it was proposed that s-SHIP, like SIP-110, resulted 
from the utilization of a different transcriptional start site than full-length SHIP, 
this start site would be embedded within the intron 5/6 of SHIP.49  It was recently 
shown that the intron 5/6 contains a promoter region that can drive the 
expression of a green fluorescent protein (GFP) construct in knock-in mice 
stem/progenitor cells, including regions where breast mammary stem cells 
reside.55  Interestingly, others observed that SHIP-deficient ES cells express s-
SHIP at higher levels and for a longer period of time when primed to differentiate 
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than WT ES cells.365  Since s-SHIP appears to be selectively expressed in ES 
cells and HSC, but not in lineage differentiated cells,49 we were interested in 
studying the signaling pathways in which this protein might be involved. 
 
s-SHIP and ES Cell 
 
 ES cells maintain pluripotency through stimulation of several signaling 
pathways.366  In vitro culture of murine ES (mES) cells requires the presence of 
fibroblast feeder layer cells and/or LIF when grown on gelatin-coated 
paltes.339,340,367  LIF engages the heterodimeric receptor complex composed of 
gp130 and LIF receptor (LIFR) and supports the culture of mES cells in the 
absence of a feeder layer.368  Several signal transduction molecules have been 
shown to play a role in the survival, self-renewal, and/or proliferation of mES cells 
via the LIFR/gp130 axis, such as Stat3,349 PI3K,350 Erk,337 and Shp-2.347  
Interestingly, the activation and formation of protein complexes among these 
different proteins establishes the delicate balance between self-renewal and 
differentiation pathways in pluripotent stem cells.337 
 
 
In different cell models, several signaling pathways important for 
proliferation and survival downstream of PI3K can be downregulated by inositol 
phosphatases such as PTEN,364,369 SHIP1, 3 and SHIP2.77,370,371  In particular, 
SHIP1 can be recruited to the membrane, where it can hydrolyze the 5’-
phosphate of PI(3,4,5)P3 or I(1,3,4,5)P4.2  In this manner, these inositol 
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phosphatases oppose the activity of PI3K by preventing the recruitment of 
pleckstrin homology (PH) containing kinases such as Akt and Btk.  Previously, 
we found that ES cells and, to a lesser extent, HSC, express an isoform of 
SHIP1, s-SHIP.  This isoform is not expressed in normal mature hematopoietic 
cells, making this molecule an excellent candidate as a key factor in the 
regulation of stem cell signal transduction pathways. 
 
In previous studies, we showed that s-SHIP interacts with Grb2 and does 
not with Shc.49  In this present study, we show that s-SHIP is expressed by mES 
cells, but not by the mouse embryonic fibroblasts (MEF) that support their 
undifferentiated growth.  MEF cells, however, do express the full-length SHIP 
isoform.  In addition, we demonstrate that murine BM cells lacking the promoter 
and first exon of the full-length SHIP gene still express s-SHIP.  This result 
confirms that expression of s-SHIP is not dependent on the upstream promoter 
active in differentiated cells.  Knowing that the major growth factor for ES cell 
self-renewal and proliferation is LIF (Figure 34), we used this growth factor to 
stimulate ES cells to determine if it can stimulate s-SHIP phosphorylation.  We 
observed that s-SHIP does not become tyrosine phosphorylated following 
stimulation of ES cells with LIF.  Finally, we show that s-SHIP associates with 
gp130 in vivo in ES cells.  These findings implicate s-SHIP in signaling pathways 
that control the self-renewal and differentiation of pluripotent stem cells. 
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Aims: 
1) Define if s-SHIP is expressed in MEF and SHIP-/- BM cells. 
2) Study what pathway s-SHIP might impact 
 
Results 
MEF Cells Express Full-Length SHIP, but Only ES Cells Express the s-SHIP 
Isoforms 
 
In our previous study, we analyzed SHIP and s-SHIP protein expression in 
ES cells after transfer from MEF feeder layer to gelatin-coated dishes.49  
Occasionally, we would find by Western blot analysis that some ES cell cultures 
grown on gelatin would express some levels of the full length SHIP isoform.49  
We attributed this to residual contamination of the ES cell culture with MEF.  To 
resolve this issue, we established a culture of MEF cells alone, ES cells on MEF 
cells, and ES cells on gelatin.  Our suspicion that MEF cells express SHIP was 
confirmed as we found that MEF express the 145/135kDa full-length SHIP 
doublet, but not the s-SHIP 104/97kDa doublet (Figure 35).  In a culture of ES 
cells growing on MEF cells, SHIP and s-SHIP are present (Figure 35).  The 
protein lysate used in the third lane was produced using ES cells propagated on 
gelatin-coated dishes in the presence of LIF for several passages.  This was 
done to reduce as much as possible the contribution of MEF cells to the analysis.  
The protein lysate of these ES cells, grown on gelatin, revealed that these cells 
express only the s-SHIP doublet (Figure 35). 
 
135 
  
 
 
 
 
Figure 35.  MEF cells express full-length SHIP, while ES cells express only s-SHIP.  
Protein lysates from MEF cells grown alone, ES cells grown on MEF cells, and ES cells 
grown on gelatin were analyzed for the expression of the different SHIP isoforms.  
Western blot was performed using the Novex/Invitrogen system.  SHIP and s-SHIP were 
revealed using P2C6 anti-SHIP antibody and anti-mouse-HRP.  Chemoluminescence 
was detected using SuperSignal Femto (Pierce Biotechnology Inc.). 
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SHIP-/- Murine BM Cells Express s-SHIP 
 
In our laboratory, we established a SHIP-/- mouse model by deletion of the 
promoter and exon 1 of the SHIP gene using the Cre-loxP technology.43  This 
deletion led to the ablation of SHIP production.43  As previously published, 
bioinformatic analysis predicted that the s-SHIP and SIP-110 promoter is in the 
intron 5/6 of the SHIP gene.49  Therefore, we theorized that SHIP-/- HSC might 
retain s-SHIP expression, since the internal promoter in intron 5/6 is intact in this 
SHIP-/- model.  As we anticipated, s-SHIP mRNA is detected in SHIP-/- BM cells 
by nested RT-PCR (Figure 36).  This result is consistent with a study by 
Rohrschneider et al (2005), in which the s-SHIP promoter region in SHIP intron 
5/6 promotes transcription of a reporter gene in stem and or early progenitor cells 
of a transgenic mouse model.55 
 
 
Figure 36.  Nested RT-PCR detection of s-SHIP expression in SHIP-/- BM.  Nested RT-
PCR was performed, using sets of primers that span the SSR (1-44) region, unique to s-
SHIP.  Initial round of amplification (43 cycles) with primers F1-25 and R459-478, 
secondary round of amplification (43 cycles) with primers F21-41 and R439-463.  
Amplified DNA was then resolved on a 2% agarose gel.  Legend: 1) Hela cells, 2) WT 
WBM C57BL6, 3) SHIP-/- WBM C57BL6, 4)WT WBM BalbC, 5) no RNA, 6) No RTase 
with RNA from WT C57BL6 BM cells, 7) No polymerase with RNA from WT C57BL6 BM 
cells). 
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s-SHIP Does Not Become Phosphorylated Following LIF Stimulation 
 
The SHIP isoform expressed in mature hematopoietic cells is tyrosine 
phosphorylated upon stimulation by growth factor,1,21,372 immune 
complexes,5,34,372,373 or BCR engagement.33,372,374  Phosphorylated SHIP is found 
associated with the adapter protein Shc, which facilitates its recruitment to the 
plasma membrane33 where it can then act on phosphatidylinositol substrates.  
However, we found that s-SHIP is not tyrosine phosphorylated in either ES cells 
grown in LIF at steady state or ES cells deprived of LIF for 5 hours and 
subsequently stimulated with 2× LIF (Figure 37).  It was also observed that s-
SHIP does not associate with Shc either at steady-state or after LIF stimulation.49  
Instead, s-SHIP co-immunoprecipitates with Grb2.49  Furthermore, it has been 
observed that SHIP or SIP110 do not need to be phosphorylated to exert their 
catalytic effect.54  Thus, it is highly probable that s-SHIP, can control PI(3,4,5)P3 
accumulation in ES cells, despite not being phosphorylated. 
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Figure 37.  ES cells express the s-SHIP protein isoform that does not become 
phosphorylated following growth factor stimulation.  Immunoprecipitation and 
immunoblot detection of s-SHIP in ES cell lysates. Lysate from ES-TL1 cells cultured in 
LIF was immunoprecipitated with the P2C6 anti-SHIP monoclonal antibody, separated 
on gels, transferred to membranes, and probed with P2C6, revealing 104-kd and 97-kd 
proteins (lane 5). No tyrosine phosphorylation of these proteins was detected when they 
were probed with the 4G10 anti-phosphotyrosine antibody. For comparison, lysates from 
293T cells transfected with SHIP cDNA (lane 1) and s-SHIP cDNA (lane 2) were 
included in the blots. To further assess the tyrosine phosphorylation status of s-SHIP, 
timed LIF stimulation studies were performed. ES-TL1 cells incubated for 5 hours 
without LIF were stimulated with 2000 U/ml LIF for 0, 2, 5, or 10 minutes and were 
rapidly lysed. Equal amounts of total protein were immunoprecipitated with the P2C6 
antibody and probed separately with the P2C6 and 4G10 antibodies (lanes 6-9). No 
tyrosine phosphorylation of s-SHIP was detected at any time point with the 4G10 
antibody. For comparison, A20 B-lymphoid cells were stimulated with anti-IgG antibody 
for 0 or 5 minutes, lysed, immunoprecipitated with P2C6, and probed with P2C6 and 
4G10 (lanes 3,4), showing prominent tyrosine phosphorylation of SHIP at 5 minutes. 
Molecular mass standards are indicated on the right. Collaboration with J. Ninos MD. 
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s-SHIP Associates with gp130 In Vivo 
 
Grb2 has been shown to be present in protein complexes formed after 
gp130 engagement. Since Grb2 can associate with s-SHIP, we assessed the 
potential of s-SHIP to associate with gp130 in ES cells.  As demonstrated in 
Figure 38A and B, s-SHIP is present in gp130 immunoprecipitates from protein 
lysates of ES cells at steady state.  This result strongly suggests that s-SHIP is 
present in protein complexes that interact with gp130 in ES cells.  Inhibition of the 
s-SHIP/gp130 association by preincubation of gp130 antibody with specific 
blocking peptides establishes the specificity of the interaction (Figure 38B).  This 
result provides a direct link between s-SHIP and an important signaling 
component of the pathway influencing ES cell self-renewal. 
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Figure 38.  s-SHIP is associated with gp130 in ES cells.  A) Lysates of ES cells grown 
on gelatin were immunoprecipitated with gp130 antibody, s-SHIP antibody (positive 
control) and rabbit antibody (negative control). (B) Lysates of ES cells grown on gelatin.  
Whole cell lysate (positive control), immunoprecipitate with gp130 antibody, 
immunoprecipitation with gp130 antibody previously blocked with specific peptides, 
immunoprecipitate with Grb2 antibody, immunoprecipitation with Grb2 antibody 
previously blocked with specific peptides, and immunoprecipitate with rabbit antibody 
(negative control). 
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Discussion 
 
In this study, we show that s-SHIP co-immunoprecipitates with gp130.  
This further suggests that s-SHIP can be found intimately associated with protein 
complexes that impact self-renewal and proliferation pathways of mES cells.  s-
SHIP may interact with gp130 directly, or indirectly, through an intermediate such 
as Grb2.  The exact role that s-SHIP plays in ES cell biology remains to be 
defined.  As shown previously, s-SHIP is found constitutively at the plasma 
membrane in ES cells.49  Furthermore, it has been shown previously that SIP110 
phosphorylation is not required for enzymatic activity.  Thus, s-SHIP could 
downregulate basal activation of Akt in these cells through degradation of 
PI(3,4,5)P3.363  In this context, the role of s-SHIP would be to limit cell survival 
(Figure 34).  Interestingly, PI3K inhibition leads to a decrease in PI(3,4,5)P3, 
resulting in Erk activation and a reduction in self-renewal.  Therefore, s-SHIP 
may negatively control ES cell self-renewal.  Since PTEN appears to be 
necessary for the control of pathway downstream of PI3K in ES cells,364 s-SHIP 
and PTEN might have a redundant role in controlling this pathway. 
 
Alternatively, s-SHIP would associate with Grb2 to prevent the formation 
of the protein complex composed of Shp-2, Grb2, and SOS, and thereby limit the 
activation of MAPK and the downstream differentiation of ES cells (Figure 34).  In 
previous studies, it was shown that s-SHIP expression declines as the stem cell 
differentiates into specific lineages.49,365  Furthermore, SHIP-/- ES cells express 
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higher levels of s-SHIP and for a longer period of than WT ES cells.365  Thus, ES 
cells might express the s-SHIP isoform to inhibit differentiation stimuli, since it 
binds Grb2 constitutively, potentially preventing the association of Shp-
2/Grb2/SOS protein complexes (Figure 34). 
 
Interestingly, the SHIPΔIP/ΔIP mice, produced by targeting the inositol 
phosphatase domain, are viable,97 despite the likelihood that they do not express 
an enzymatically active form of s-SHIP.  However, analysis of s-SHIP expression 
in primitive cell types or BM cells has not been demonstrated for this SHIP KO 
model.  To date, there does not exist an s-SHIP-/- model, which maintains WT 
levels of full length SHIP, therefore it will be difficult to truly assess the role of s-
SHIP in stem cell biology until such a mouse model is developed.  In the 
meantime, studies in ES cells using RNA interference techniques to target s-
SHIP expression will be useful in understanding the contribution of this protein in 
the control of self-renewal and differentiation in pluripotent stem cells.  Most 
importantly, more studies are needed to completely define the relationship 
between s-SHIP, Grb2, and gp130 and their combined role in ES cell function. 
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Materials and methods 
Propagation of mES Cells 
 
For our studies, we used TL1 strain mES cells, which were a kind gift from 
Patricia A. Labosky, University of Pennsylvania, Philadelphia, Pennsylvania, 
USA.  mES cells were first thawed on MEF cells and then transferred and 
passaged on gelatin-coated dishes.  Petri dishes (100mm plates, Nunc, Fisher 
Scientific Inc. Suwanee, GA) were covered with 0.1% gelatin in ultrapure water 
(Chemicon International/Specialty Media, Phillipsburg, NJ, USA) for at least 30 
minutes.  The extra gelatin was then removed.  Cells were cultured in KO DMEM 
media (Gibco BRL/Invitrogen), 15% ES cell qualified FBS (Invitrogen/Gibco 
BRL), 2 mM L-Alanyl-L-Glutamine (ATCC, Manassas, VA, USA), 0.1 mM Non-
essential amino acids (Gibco BRL/Invitrogen), 0.1 mM β-mercaptoethanol (β-ME) 
(Sigma-Aldrich) with 1000 U/ml LIF (Chemicon International).  ES cells were split 
every other day using a 0.05% trypsin-EDTA treatment for 3-5 minutes. 
 
Preparation of mES Cell Lysates for Biochemical Analysis 
 
ES cells were grown in the presence of 1000 U/ml LIF.  In preparation for 
cell lysis, ES cells cell culture dish was placed on ice, the culture media was then 
removed and the cells were washed twice with PBS containing 1 mM sodium 
pervanadate (NaVO3).  ES cells were then lysed with modified RIPA buffer 
(Upstate) containing 1 mM NaVO3 and protease inhibitor (Sigma-Aldrich).  Lysis 
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was performed at 4oC for 45 to 60 minutes.  Protein concentration was 
established using the BCA protein assay kit (Pierce Biotechnology Inc.). 
 
Nested Reverse-Transcription Polymerase Chain Reaction Assay for Detection 
of s-SHIP Expression 
 
Murine BM cells were isolated as mentioned previously.  RNA was 
isolated from 1x106 WT and SHIP-/- BM cells following the protocol for the 
RNAqueous-4PCR kit (Ambion).  RT-PCR was performed using MultiScribe 
reverse transcriptase (Applied Biosystems) protocol.  Briefly, 5xRT-PCR buffer (4 
μl), 25 mM MgCl2 (2 μl), 10 mM dNTP (2 μl), RNase inhibitor (0.5 μl), 100 mM 
DTT (2 μl) and random hexamers (0.5 μl) were mixed with RNase free water (up 
to 20 μl) and RNA isolated from tested samples (equivalent of 1x104 cells).  
MultiScribe RTase enzyme, 0.3 μl, was then added to the reaction, for a total 
volume of 20 μl.  The RT reaction was performed in a Px2 thermal cycler PCR 
machine (Thermo Electron Corporation, Waltham, MA) using the following 
program: 10 minutes at 25oC and then 12 minutes at 42oC.  The RT products 
were placed at 4oC for 1-2 hours.  Ten μl of the RT reaction product was then 
used for PCR amplification using a forward primer specific for the s-SHIP SSR 
region and a reverse primer specific for a region approximately 460 bp 
downstream of the s-SHIP SSR region.49  Briefly, cDNA (10 μl), RNase free 
water (25 μl), 5x Amplitaq buffer (8 μl), 25 mM MgCl2 (2.5 μl), 10nM dNTP (3 μl), 
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20 μM s-ship forward (1-25) and reverse (459-478) primers (0.5 μl each) and 0.5 
μl of AmpliTaq (Applied Biosystems) were mixed prior to PCR amplification.  
Amplification was performed in a Px2 thermal cycler PCR machine using the 
following program: 10 minutes denaturation at 95oC followed by 43 cycles of 25 
seconds at 94oC and 1 minute at 55oC, with a final extension phase at 72oC for 7 
minutes.  Twenty μl of the PCR reaction was then placed in a second PCR using 
the same conditions, except that the primers were internal to the first round 
amplification primers and targeted the s-SHIP nucleotides 21-41 (forward 
primer), within the SSR region, and 463-478 (reverse primer).  All primers were 
obtained from Integrated DNA Technologies Inc. (Coralville, IA, USA).  The 
expected PCR product for the s-ship nested PCR product is 442 base pairs, 
which coincides with the product seen on a 1.2% agarose gel.  Primers used for 
s-SHIP nested PCR:  Initial amplification: forward(1-25), 5’-gtt ccc act agt tgt tga 
act tta c-3’ and reverse(478-459), 5’-tct cct tct ccg tct cca cc-3’; secondary 
amplification: forward(21-41), 5’-ttt acc ttg aac ctc tgc tcc-3’ and reverse(463-
439) 5’-cca cca aaa tca cca act tgt tta g-3’. 
 
Western blot antibodies and techniques 
 
The Western blots apparatus consisted of the Novex X-cell II system with 
Bis-Tris gel system (Novex/Invitrogen).  Typically 4 to 12% gels were used 
(Novex/Invitrogen).  Gels were run at RT for 2 hours at 150 Volts. Multi-Mark or 
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BenchMark (Novex/Invitrogen) protein ladders were used to correlate molecular 
weight of target proteins.  Proteins were electrophoretically transferred to 
nitrocellulose membranes (Millipore, Billerica, MA, USA) for immunoblotting.  The 
blots were initially washed twice for 2 minutes in a solution of PBS 0.05% Tween 
(PBS-T), then blocked for 1 hour at RT in 5% NFM in PBS with 0.05% Tween 
(5% NFM/PBS-T).  The blots were washed 3 x 5 minutes in PBS-T and then 
incubated overnight at 4oC in anti-SHIP monoclonal antibody solution of P2C6 
antibody (a kind gift from Dr. Larry Rohrschneider) at a concentration of 1:1000, 
or the P1C1 monoclonal antibody (Santa Cruz Biotechnology Inc., Santa Cruz, 
CA) at a concentration of 1 μg/ml in 5%NFM/PBS-T.  The following day, blots 
were washed at least three times for 10 minutes and incubated with anti-mouse-
HRP conjugated antibody (Pierce Biotechnology Inc.) at concentration 1:80,000 
for 2 hours at RT.  The blot was then washed four times 5 minutes in PBS-T and 
exposed with SuperSignal West Femto for 5 minutes (Pierce Biotechnology Inc.). 
 
Cell stimulation 
ES-TL1 cells were split into 4 different 100-mm TC plates and grown 
overnight at 37oC in ES media supplemented with 1000 U/ml LIF to approximate 
80% confluence. LIF-supplemented media was removed, cells were washed 
twice with PBS, media without LIF was added, and cells were incubated for 5 
hours. Cells were washed once with PBS and twice with Hanks balanced salt 
solution (HBSS, Mediatech). Then they were pre-incubated in HBSS at 37oC for 
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10 minutes. Cells were stimulated by the addition of HBSS containing 2000 U/ml 
LIF and by incubation at 37oC for either 2, 5, or 10 minutes. A control ES plate (0 
minute) containing HBSS without LIF was incubated at 37oC in parallel for 10 
minutes. Stimulations were stopped by the removal of buffer and the addition of 
10 ml ice-cold PBS/1 mM Na3VO4. PBS/Na3VO4 was removed, and 1mL ice-cold 
modified RIPA buffer was added immediately. Cells were scraped, and cell 
lysates were processed as described above. A20 cells were grown in RPMI and 
were washed once with PBS and twice with HBSS. Then 2×107 cells were placed 
in separate 15-mL conicals and were pre-incubated in HBSS at 37oC for 10 
minutes. Cells were spun down, and HBSS was removed. After that, cells were 
stimulated with 1 ml HBSS containing 20 μg/ml goat anti-mouse IgG (Southern 
Biotechnology Associates, Birmingham, AL) and were incubated at 37oC for 5 
minutes. Control A20 cells (0 minute) containing HBSS without anti-mouse IgG 
were incubated in parallel. Stimulations were stopped by placing the conicals on 
ice and adding 2 ml ice-cold PBS/Na3VO4. Cells were pelleted, supernatant was 
removed, and 1 ml ice-cold modified RIPA buffer was added.  One mg in 1 ml of 
buffer was used for subsequent immunoprecipitation experiments. 
 
Western blot analysis of gp130 immunoprecipitates 
 
Equivalent amounts of protein lysate were first pre-cleared twice with 0.25 
μg of appropriate nonspecific IgG isotype control followed by 50 μl of appropriate 
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50% agarose bead slurry (Protein A or G) (Upstate).  The beads had previously 
been washed three times in cold PBS.  They were then resuspended in PBS 
containing 1mM NaVO3 to obtain a 50% slurry.  The pre-cleared lysates were 
then exposed to specific polyclonal antibodies against gp130 (M-20) (Santa Cruz 
Biotechnology) and Grb2 (Santa Cruz Biotechnology) for 3 hours at 4oC on a 
rotator.  When peptide blocked antibodies were used for immunoprecipitation, 
gp130 and Grb2 antibodies were incubated with their respective blocking 
peptides (Santa Cruz Biotechnology) for at least 1 hour on a rotator at 4ºC prior 
to being used for immunoprecipitation.  Once incubation with antibody was 
completed, 50 μl of Protein A or G agarose beads 50% slurry was then added to 
the immunoprecipitates and put on a rotator overnight at 4oC.  The following day, 
the supernatant was removed and beads were washed four times with FROP 
buffer (150 mM NaCl, 5 mM CHAPS, 50 mM Tris pH 8).  LDS sample buffer with 
reducer (Novex/Invitrogen) was then added to the beads, and the bead/buffer 
mixture was heated at 100oC for 5 minutes.  Western blot analysis was then 
performed as described above. 
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FINAL DISCUSSION 
 
One might be surprised to notice that through out this dissertation, SHIP is 
given multiple roles.  For example, in HSC we attributed to SHIP the ability to 
impact proliferation, survival, homing and retention to the BM.  In addition, a 
similar scenario was observed when we studied the role of SHIP in MKP.  
However, when we truly look at each of the signaling pathways that can be 
influenced by SHIP, each of them can be linked to a function attributed to SHIP.  
This protein can control proliferation through the regulation of the MAPK by 
sequestration of Shc.1  Alternatively, it can contribute in the negative regulation of 
the Akt signaling pathway, which promotes cell survival and proliferation.61  
Furthermore, SHIP was shown to negatively control myeloid progenitor cell 
response to SDF-1, SHIP-/- myeloid progenitors being more responsive to SDF-1 
stimulation than WT.152  Additionally, SHIP by being a major regulator of the PI3K 
downstream effector pathway can impact hematopoietic cell response to diverse 
cytokines.  Interestingly, PI3K is also known to bind to focal adhesion kinase 
(FAK),375 and in this pathway, PI3K activation leads to the production of PI(3,4,5)P3 
which contributes to the control of cell motility by FAK.  Thus, SHIP could 
contribute to the negative regulation of this pathway.  Moreover, we observed 
that SHIP appears to contribute to the shaping of the NK cell receptor repertoire.  
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Our results suggest that SHIP regulates the NK cell receptor repertoire diversity 
through promotion of survival of certain NK cell subset.  However, we can not 
exclude that SHIP could also participate in NK cell receptors transcription 
regulation.  SHIP has been shown to influence I-κB activity, which regulates 
NFκB function.  Most interestingly, NF-κB was shown to contribute to the 
regulation of Ly49 receptor expression.331  More studies are needed to truly 
define the role of SHIP in all these different pathways.  Furthermore, it is 
necessary to establish which isoform or isoforms are involved in each of these 
pathways in every cell type, since each isoform contains different combination of 
functional domains.  
 
After studying SHIP for 5 years, it is clear to me that it plays different roles 
depending on the hematopoietic cells type, the cell context, and the cell 
environment.  Another testament to its variegated role in the control of cellular 
function is the fact that SHIP has several isoforms and that each of them appear 
to be expressed differently in diverse cell types.4,49,53  In theory, every SHIP 
isoform still contains a functional 5’ inositol phosphatase enzymatic domain.  
Phosphatidylinositols are used to transmit signal from different external stimuli to 
activate cellular response that can lead to calcium mobilization, protein 
phosphorylation, cell proliferation, activation and survival.  Therefore, SHIP has 
the potential to influence each of these pathways.  However, the fact that these 
SHIP isoforms lack some of the protein interaction domain, will modify the 
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cellular context in which these isoforms will be recruited to the membrane or site 
of action.  For example s-SHIP, which has no SH2 domain, will be restricted in its 
ability to interact with phosphorylated tyrosine.  Another isoform, SHIPΔ183, 
lacks a region between the two NPXY leading to a disruption of a consensus 
sequence necessary for the binding of PI3K p85 subunit.  Interestingly, the 
different isoform appear to be differentially expressed by diverse cell type.  This 
can provide the cell with an isoform that will correspond to the need of that 
particular cell.  For example, ES cells express only s-SHIP and not full length 
SHIP, while HSC express both isoforms.49  It was also shown that untreated 
human BM cells express a 110kDa isoform, but when the same cells were 
treated in vitro with IL-3 and M-CSF to promote differentiation towards the 
myeloid lineage, full length SHIP was observed.53 
 
Noteworthy are the observations linking SHIP-deficiency to premature 
aging.  For example SHIP-deficient mice suffer from osteoporosis due to hyper-
responsive osteoclasts.101  Furthermore, SHIP-/- BM have an increased number 
of HSC, which are not as efficient as WT at reconstituting an irradiated host.156,246  
Moreover, the SHIP-/- hematopoietic system is skewed towards myeloid cell 
differentiation.95  All of these are characteristics that have been associated with 
aging.376-383  It would be interesting to address the hypothesis that SHIP 
deficiency causes accelerated aging in mice. 
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Although SHIP is known to influence many signaling pathways in different 
cell types, its deficiency is not associated with many diseases.  SHIP appears to 
be absent in some forms of acute leukemias.384  It was also associated with 
myeloproliferative disorder95 and with osteoporosis.101  Nevertheless, the study of 
the germline SHIP-/- mouse model did not allow confirming that SHIP mutation 
might be associated with any other disease, yet.  It will be important to study the 
conditional knock-out system to establish more precisely if SHIP deletion or 
mutation during adulthood might participate in the development of cancers, 
allergic, auto-immune or inflammatory condition. 
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